CA2296654A1 - Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity - Google Patents
Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity Download PDFInfo
- Publication number
- CA2296654A1 CA2296654A1 CA002296654A CA2296654A CA2296654A1 CA 2296654 A1 CA2296654 A1 CA 2296654A1 CA 002296654 A CA002296654 A CA 002296654A CA 2296654 A CA2296654 A CA 2296654A CA 2296654 A1 CA2296654 A1 CA 2296654A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical
- tannic acid
- tannin
- liquid composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 222
- 229920000642 polymer Polymers 0.000 title claims abstract description 182
- 238000013270 controlled release Methods 0.000 title claims abstract description 64
- 210000000214 mouth Anatomy 0.000 title claims description 41
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 18
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 120
- 229920002258 tannic acid Polymers 0.000 claims abstract description 120
- 229940033123 tannic acid Drugs 0.000 claims abstract description 120
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 113
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 113
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 113
- 229920001864 tannin Polymers 0.000 claims abstract description 90
- 235000018553 tannin Nutrition 0.000 claims abstract description 90
- 239000001648 tannin Substances 0.000 claims abstract description 90
- 239000003814 drug Substances 0.000 claims abstract description 67
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract 27
- 102000004169 proteins and genes Human genes 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 77
- 108010010803 Gelatin Proteins 0.000 claims description 75
- 229920000159 gelatin Polymers 0.000 claims description 75
- 239000008273 gelatin Substances 0.000 claims description 75
- 235000019322 gelatine Nutrition 0.000 claims description 75
- 235000011852 gelatine desserts Nutrition 0.000 claims description 75
- 229960002715 nicotine Drugs 0.000 claims description 74
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 74
- 239000007788 liquid Substances 0.000 claims description 71
- 239000008247 solid mixture Substances 0.000 claims description 70
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 239000002502 liposome Substances 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 55
- 230000001070 adhesive effect Effects 0.000 claims description 51
- 239000002244 precipitate Substances 0.000 claims description 50
- 239000000853 adhesive Substances 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 33
- 239000003094 microcapsule Substances 0.000 claims description 29
- 108010088751 Albumins Proteins 0.000 claims description 24
- 102000009027 Albumins Human genes 0.000 claims description 24
- 229920001436 collagen Polymers 0.000 claims description 24
- 108010035532 Collagen Proteins 0.000 claims description 23
- 102000008186 Collagen Human genes 0.000 claims description 23
- 239000004005 microsphere Substances 0.000 claims description 22
- 239000002088 nanocapsule Substances 0.000 claims description 22
- 239000002077 nanosphere Substances 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 239000004014 plasticizer Substances 0.000 claims description 20
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 19
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 19
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 15
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 229960002390 flurbiprofen Drugs 0.000 claims description 14
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 14
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 12
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 12
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 9
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 239000001814 pectin Substances 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 150000004804 polysaccharides Chemical class 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000003408 sphingolipids Chemical class 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 229960000807 dihydroergotamine mesylate Drugs 0.000 claims description 3
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 claims description 3
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 3
- 229960004943 ergotamine Drugs 0.000 claims description 3
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 3
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 3
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 3
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 3
- 229960003827 isosorbide mononitrate Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001597 nifedipine Drugs 0.000 claims description 3
- 229960000770 ondansetron hydrochloride Drugs 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 229960000292 pectin Drugs 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 229960002702 piroxicam Drugs 0.000 claims description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 229940083466 soybean lecithin Drugs 0.000 claims description 3
- 239000008348 synthetic phosphatidyl choline Substances 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 235000006491 Acacia senegal Nutrition 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960000658 sumatriptan succinate Drugs 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims 13
- 239000006193 liquid solution Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 abstract description 19
- 239000012730 sustained-release form Substances 0.000 abstract description 17
- 230000000699 topical effect Effects 0.000 abstract description 8
- 230000009885 systemic effect Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 88
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 41
- 238000009472 formulation Methods 0.000 description 32
- 239000013543 active substance Substances 0.000 description 30
- 239000000843 powder Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 238000000338 in vitro Methods 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 19
- 230000001186 cumulative effect Effects 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 238000012384 transportation and delivery Methods 0.000 description 14
- -1 fentizac Chemical compound 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 210000003296 saliva Anatomy 0.000 description 11
- 239000000227 bioadhesive Substances 0.000 description 10
- 239000010408 film Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 239000012669 liquid formulation Substances 0.000 description 10
- 210000002200 mouth mucosa Anatomy 0.000 description 10
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 9
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229960001416 pilocarpine Drugs 0.000 description 9
- 230000002035 prolonged effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229960004025 sodium salicylate Drugs 0.000 description 7
- 150000001860 citric acid derivatives Chemical class 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920003139 Eudragit® L 100 Polymers 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- 229920000161 Locust bean gum Polymers 0.000 description 4
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 239000012790 adhesive layer Substances 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940112822 chewing gum Drugs 0.000 description 4
- 235000015218 chewing gum Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 235000010420 locust bean gum Nutrition 0.000 description 4
- 239000000711 locust bean gum Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001479489 Peponocephala electra Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 229940043432 albumin tannate Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000006189 buccal tablet Substances 0.000 description 3
- 239000003975 dentin desensitizing agent Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008376 breath freshener Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012374 esterification agent Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 2
- 229950004155 etorphine Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000008016 pharmaceutical coating Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940124535 smoking cessation aid Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000008377 tooth whitener Substances 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 229940044977 vaginal tablet Drugs 0.000 description 2
- 239000000003 vaginal tablet Substances 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- ZDPACSAHMZADFZ-UHFFFAOYSA-N 1-[3-(2,4,6-Trimethoxybenzoyl)propyl]pyrrolidinium chloride Chemical compound [Cl-].COC1=CC(OC)=CC(OC)=C1C(=O)CCC[NH+]1CCCC1 ZDPACSAHMZADFZ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- QVHDNNXTFDGCME-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-hydroxybenzoate;hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1O QVHDNNXTFDGCME-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- FSSICIQKZGUEAE-UHFFFAOYSA-N 2-[benzyl(pyridin-2-yl)amino]ethyl-dimethylazanium;chloride Chemical compound Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 FSSICIQKZGUEAE-UHFFFAOYSA-N 0.000 description 1
- ZXSGQNYQJIUMQN-UHFFFAOYSA-N 3-(2-methylpiperidin-1-ium-1-yl)propyl benzoate;chloride Chemical compound Cl.CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 ZXSGQNYQJIUMQN-UHFFFAOYSA-N 0.000 description 1
- NOXNCSQBTYNMHD-UHFFFAOYSA-N 3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine;hydron;chloride Chemical compound Cl.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 NOXNCSQBTYNMHD-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- RZOXEODOFNEZRS-UHFFFAOYSA-N Tramazoline hydrochloride Chemical compound [Cl-].N1CCN=C1[NH2+]C1=CC=CC2=C1CCCC2 RZOXEODOFNEZRS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 239000012711 adhesive precursor Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002113 buflomedil hydrochloride Drugs 0.000 description 1
- 229960005064 buserelin acetate Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229940078916 carbamide peroxide Drugs 0.000 description 1
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 description 1
- 229960002631 carbazochrome Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- SZKQYDBPUCZLRX-UHFFFAOYSA-N chloroprocaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl SZKQYDBPUCZLRX-UHFFFAOYSA-N 0.000 description 1
- 229960002038 chloroprocaine hydrochloride Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960003140 clofezone Drugs 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229960004992 maprotiline hydrochloride Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960001397 methdilazine hydrochloride Drugs 0.000 description 1
- IEISBKIVLDXSMZ-UHFFFAOYSA-N methdilazine hydrochloride Chemical compound Cl.C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 IEISBKIVLDXSMZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 1
- 229960000923 metoclopramide hydrochloride Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
- 229960001070 mexiletine hydrochloride Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004186 naphazoline nitrate Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960004790 phenelzine sulfate Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003253 procainamide hydrochloride Drugs 0.000 description 1
- ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000007852 tooth bleaching agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- 229960000732 tripelennamine hydrochloride Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960000881 verapamil hydrochloride Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention is directed to controlled- or sustained-release compositions for the release of pharmaceuticals or other agents. Essential components in the compositions of the present invention include one or more polymers and tannic acid or tannin. Release of the pharmaceutical or other agent is for a predetermined period of time and at a predetermined concentration. The site of action of the agent is topical, local or systemic. Polymers are cellulosic or proteinaceous.
Description
Tannic Acid-Polymer Compositions for Controlled Release of Pharmaceutical Agents, Particularly in the Oral Cavity Background of the Invention Field of the Invention The field of the invention is controlled or sustained release compositions for the release of one or more pharmaceuticals or other agents. Essential components in the compositions of the present invention include one or more polymers and tannic acid or tannin. Release of the desired agent can be adjusted to a predetermined period of time and for ~ predetermined concentration. The site of action of the agent is topical, local or systemic. Polymers are cellulosic or protemaceous.
Related Art Controlled-release products are well known in the pharmaceutical field and are used to maintain a desired level of medicament over a desired period of time while increasing patient compliance by reducing the number of administrations necessary to achieve the desired level.
Compositions Comprising Polymers and Tannic Acid or Tannin Calderon et al., J. Agr. Food Chem. 16:479 (1968), compared tannic acid and quebracho tannin coprecipitation with gelatin to form gelatin/tannin precipitates. Calderon disclosed that proteins as different as egg albumin and gelatin readily combine with tannins to form precipitates. Calderon addressed the problem of the formation of precipitates between proteins and tannins in natural beverages such as fi~uit juice, wines and beer, and further explored the possibility that adding a protein, such as gelatin, to the hazy solution could entrap haze
Related Art Controlled-release products are well known in the pharmaceutical field and are used to maintain a desired level of medicament over a desired period of time while increasing patient compliance by reducing the number of administrations necessary to achieve the desired level.
Compositions Comprising Polymers and Tannic Acid or Tannin Calderon et al., J. Agr. Food Chem. 16:479 (1968), compared tannic acid and quebracho tannin coprecipitation with gelatin to form gelatin/tannin precipitates. Calderon disclosed that proteins as different as egg albumin and gelatin readily combine with tannins to form precipitates. Calderon addressed the problem of the formation of precipitates between proteins and tannins in natural beverages such as fi~uit juice, wines and beer, and further explored the possibility that adding a protein, such as gelatin, to the hazy solution could entrap haze
-2-particles and decrease tannin in the beverage. Calderon was not directed to any use for the precipitates, and did not further characterize them.
U.S. PatentNo. 3,255,018 discloses an adhesive chewing gum containing a tannic acid and gelatin complex. This complex is added to make the gum base non-adhesive to the teeth.
U.S. Patent No. 3,679,792 discloses a chewing gum composition having anti-caries activity. The chewing gum contains a gelatin-tannic acid adduct used as an adhesive to counteract the tendency of chewing gum compositions to adhere to teeth, and particularly to certain types of dentures and artificial teeth.
U.S. Patent No. 4,274,410 discloses an infra-vaginal contraceptive and drug-release sponge. The document discloses a collagen slurry and a tanning agent to cross-link the collagen.
U.S. Patent No. 5,223,029 discloses a hardening material for medical and dental use. Essential components include tri-calcium phosphate or tetra-calcium phosphate and a hardening adjuster that may comprise tannin and collagen. The document suggests using decomposed gelatin (water-soluble gelatin or gelatin 21, products of Nitta Gelatin Inc.). Collagen can be used by preparing a solution independent of the tannin solution, by dissolving it in the tannin solution, or by using it in its powdered state. No use, other than a hardener, and no physical characteristics of the tannin-collagen combination is given. Further, the document discloses the use of the complex for the slow release of tannic acid for the formation of a cement and not as a flexible adhesive. Further, there is no suggestion that this complex should be used for drug release or is suitable for this purpose.
Rodu et al., J. Oral Pathol. 17:324 ( 1988), evaluated the in vitro virucidal activity of soluble components of a topical film-forming medication, ZilactinTM.
ZilactinTM is a hydroxypropylcellulose-based film-forming medication. Other active ingredients include tannic acid, salicylic acid and boric acid, which are disclosed as necessary for the unique adherent film-forming properties of the medication.
U.S. PatentNo. 3,255,018 discloses an adhesive chewing gum containing a tannic acid and gelatin complex. This complex is added to make the gum base non-adhesive to the teeth.
U.S. Patent No. 3,679,792 discloses a chewing gum composition having anti-caries activity. The chewing gum contains a gelatin-tannic acid adduct used as an adhesive to counteract the tendency of chewing gum compositions to adhere to teeth, and particularly to certain types of dentures and artificial teeth.
U.S. Patent No. 4,274,410 discloses an infra-vaginal contraceptive and drug-release sponge. The document discloses a collagen slurry and a tanning agent to cross-link the collagen.
U.S. Patent No. 5,223,029 discloses a hardening material for medical and dental use. Essential components include tri-calcium phosphate or tetra-calcium phosphate and a hardening adjuster that may comprise tannin and collagen. The document suggests using decomposed gelatin (water-soluble gelatin or gelatin 21, products of Nitta Gelatin Inc.). Collagen can be used by preparing a solution independent of the tannin solution, by dissolving it in the tannin solution, or by using it in its powdered state. No use, other than a hardener, and no physical characteristics of the tannin-collagen combination is given. Further, the document discloses the use of the complex for the slow release of tannic acid for the formation of a cement and not as a flexible adhesive. Further, there is no suggestion that this complex should be used for drug release or is suitable for this purpose.
Rodu et al., J. Oral Pathol. 17:324 ( 1988), evaluated the in vitro virucidal activity of soluble components of a topical film-forming medication, ZilactinTM.
ZilactinTM is a hydroxypropylcellulose-based film-forming medication. Other active ingredients include tannic acid, salicylic acid and boric acid, which are disclosed as necessary for the unique adherent film-forming properties of the medication.
-3-Rodu et al., J. Oral Pathol. 17:564 (1988), discloses a bioadhesive agent, ZilactinTM, as a mucosal bioadhesive that is based on hydroxypropylcellulose and is complexed with three organic acids. ZilactinTM is reported to form an adherent and soluble film resulting in significant pain relief and protection of ulcers from irritants for several hours. The medication was made, among other embodiments, with a combination of hydroxypropylcellulose and tannic acid dissolved in SD40 alcohol for comparison testing with the parent compound ZilactinTM. The physical properties of this binary complex were not investigated, and no use for this complex for releasing drugs was disclosed or suggested.
U. S. Patent No. 5,081,157 discloses a film-forming composition for topical application of medicaments to body tissues. The film-forming composition includes hydroxypropylcellulose for treating skin mucosal tissue and other moist tissue by forming an adherent film. An esterification agent is an essential component of the film. A weak carboxylic acid such as tannic acid is suggested as the specific esterification agent component. The cellulosic compound is reacted with the weak carboxylic acid to form the film.
Gamiz Gracia, et al., J. Pharm. Biomed. Anal. 15:447 (1997) discloses a flow injection analysis method to determine albumin tannate in tablets.
Albumin tannate is a compound of tannic acid (tannin) with albumin (50%), used for its astringent properties in the treatment of diarrhea. This document discloses albumin tannate as a drug and not as a drug carrier. No physical properties of this compound are reported.
U. S. PatentNo. 4,524,824 discloses a dental cement in which a tannic acid derivative, consisting of a tannic acid-protein combination, is reported.
Suggested proteins include albumin and gelatin. Precipitates are formed between the tannic acid and the protein. The precipitates are used for the slow release of tannic acid for the formation of a cement and not to form a flexible adhesive. Moreover, there is no disclosure or suggestion to use such a complex to release a drug.
None of the physical characteristics of the complex is provided.
*rB
U. S. Patent No. 5,081,157 discloses a film-forming composition for topical application of medicaments to body tissues. The film-forming composition includes hydroxypropylcellulose for treating skin mucosal tissue and other moist tissue by forming an adherent film. An esterification agent is an essential component of the film. A weak carboxylic acid such as tannic acid is suggested as the specific esterification agent component. The cellulosic compound is reacted with the weak carboxylic acid to form the film.
Gamiz Gracia, et al., J. Pharm. Biomed. Anal. 15:447 (1997) discloses a flow injection analysis method to determine albumin tannate in tablets.
Albumin tannate is a compound of tannic acid (tannin) with albumin (50%), used for its astringent properties in the treatment of diarrhea. This document discloses albumin tannate as a drug and not as a drug carrier. No physical properties of this compound are reported.
U. S. PatentNo. 4,524,824 discloses a dental cement in which a tannic acid derivative, consisting of a tannic acid-protein combination, is reported.
Suggested proteins include albumin and gelatin. Precipitates are formed between the tannic acid and the protein. The precipitates are used for the slow release of tannic acid for the formation of a cement and not to form a flexible adhesive. Moreover, there is no disclosure or suggestion to use such a complex to release a drug.
None of the physical characteristics of the complex is provided.
*rB
4 ~ PCTIUS98/15096 WO 93/ 10827 discloses coating guidewires using a protein-based coating that has been pretreated by the addition of weak organic acids, for example tannic acid. Suggested proteins include gelatin, collagen and albumin. No physical characteristics are provided for the coating. Furthermore, there is no disclosure or suggestion to release a pharmaceutical from the coating.
Oral Delivery Systems Oral controlled-release delivery systems should ideally be adaptable so that release rates and profiles can be matched to physiological and chronotherapeutic requirements. The art describes free forms, such as sublingual tablets, troches, and buccals. In addition to non-attached oral sustained or controlled release forms, other forms are designed to adhere to the oral mucosa and deliver an active pharmaceutical agent either directly into the oral mucosa, or into the saliva.
Ointments and other sticky adhering compositions also have been used. The active ingredient in all these forms can act locally or systemically.
U.S. Patent No. 4,829,056 describes a buccal tablet consisting of etorphine, at least one monosaccharide, disaccharide or mixture thereof, and a mixture of xanthan gum and locust bean gum in a weight ratio of 3:1 to 1:1, wherein the total weight of the mono- and/or disaccharides relative to the combined weight of xanthan and locust bean gums is in the ratio of 20:1 to 3:1.
The buccai tablet is intended to be placed between the gingival surface of the jaw and the buccal mucosa where it gels to produce a soft hydrated tablet which may be retained in position so as to provide release of etorphine for up to two hours.
The buccal tablet is said to provide improved bioavailability.
U.S. Patent No. 4,948,580 describes a bioadhesive composition which may be employed as an oral drug delivery system and includes a freeze-dried polymer mixture formed of the copolymer poly(methyl vinyl ether/maleic anhydride) and gelatin dispersed in an ointment base. This composition is said to be useful to WO 99/04764 ~ PCT/US9$/15096
Oral Delivery Systems Oral controlled-release delivery systems should ideally be adaptable so that release rates and profiles can be matched to physiological and chronotherapeutic requirements. The art describes free forms, such as sublingual tablets, troches, and buccals. In addition to non-attached oral sustained or controlled release forms, other forms are designed to adhere to the oral mucosa and deliver an active pharmaceutical agent either directly into the oral mucosa, or into the saliva.
Ointments and other sticky adhering compositions also have been used. The active ingredient in all these forms can act locally or systemically.
U.S. Patent No. 4,829,056 describes a buccal tablet consisting of etorphine, at least one monosaccharide, disaccharide or mixture thereof, and a mixture of xanthan gum and locust bean gum in a weight ratio of 3:1 to 1:1, wherein the total weight of the mono- and/or disaccharides relative to the combined weight of xanthan and locust bean gums is in the ratio of 20:1 to 3:1.
The buccai tablet is intended to be placed between the gingival surface of the jaw and the buccal mucosa where it gels to produce a soft hydrated tablet which may be retained in position so as to provide release of etorphine for up to two hours.
The buccal tablet is said to provide improved bioavailability.
U.S. Patent No. 4,948,580 describes a bioadhesive composition which may be employed as an oral drug delivery system and includes a freeze-dried polymer mixture formed of the copolymer poly(methyl vinyl ether/maleic anhydride) and gelatin dispersed in an ointment base. This composition is said to be useful to WO 99/04764 ~ PCT/US9$/15096
-5-deliver active ingredients such as steroids, antifungal agents, and antibacterial agents, to the oral mucosa.
U.S. Patent No. 4,597,959 describes a cosmetic breath -freshener composition in wafer form which is said to have slow release properties. The composition includes a multiplicity of microencapsulated liquid droplets of flavoring material contained in an adhesive base.
U.S. Patent No. 5,077,051 describes bioadhesive microcapsules which comprise xanthan gum, locust bean gum, a bulking agent and an active agent.
The microcapsules are said to be useful for delivering buffering agents to the oral cavity for anticarious purposes. The microcapsules are prepared by preparing a hot aqueous solution or suspension of the active agent; adding xanthan gum, locust bean gum and a bulking agent to form a viscous solution; and then (a) cooling and then drying the viscous solution to obtain a solid material which is then formed into microcapsules, or (b) spray-drying the viscous solution to form the microcapsules.
U.S. Patent No. 4,915,948 describes a tablet which is said to have improved adhesion to mucous membranes. The tablet includes a water soluble biopolymer selected from xanthan gum, a pectin and mixtures thereof, and a solid polyol having a solubility at room temperature in water greater than about 20g/100g solution.
U.S. Patent Nos. 4,994,276, 5,128,143, and 5,135,757, describe a controlled release excipient comprised of synergistic heterodisperse polysaccharides (e.g., a heteropolysaccharide, such as xanthan gum in combination with a polysaccharide gum capable of cross-linking with the heteropolysaccharide, such as locust bean gum) that is capable of processing into oral solid dosage forms using either direct compression, following addition of drug and lubricant powder, conventional wet granulation, or a combination of the two. Release of the medicament from the formulations is reported to proceed according to zero-order or first-order mechanisms.
WO 99/04764 ~ PCT/US98/15096
U.S. Patent No. 4,597,959 describes a cosmetic breath -freshener composition in wafer form which is said to have slow release properties. The composition includes a multiplicity of microencapsulated liquid droplets of flavoring material contained in an adhesive base.
U.S. Patent No. 5,077,051 describes bioadhesive microcapsules which comprise xanthan gum, locust bean gum, a bulking agent and an active agent.
The microcapsules are said to be useful for delivering buffering agents to the oral cavity for anticarious purposes. The microcapsules are prepared by preparing a hot aqueous solution or suspension of the active agent; adding xanthan gum, locust bean gum and a bulking agent to form a viscous solution; and then (a) cooling and then drying the viscous solution to obtain a solid material which is then formed into microcapsules, or (b) spray-drying the viscous solution to form the microcapsules.
U.S. Patent No. 4,915,948 describes a tablet which is said to have improved adhesion to mucous membranes. The tablet includes a water soluble biopolymer selected from xanthan gum, a pectin and mixtures thereof, and a solid polyol having a solubility at room temperature in water greater than about 20g/100g solution.
U.S. Patent Nos. 4,994,276, 5,128,143, and 5,135,757, describe a controlled release excipient comprised of synergistic heterodisperse polysaccharides (e.g., a heteropolysaccharide, such as xanthan gum in combination with a polysaccharide gum capable of cross-linking with the heteropolysaccharide, such as locust bean gum) that is capable of processing into oral solid dosage forms using either direct compression, following addition of drug and lubricant powder, conventional wet granulation, or a combination of the two. Release of the medicament from the formulations is reported to proceed according to zero-order or first-order mechanisms.
WO 99/04764 ~ PCT/US98/15096
-6-U. S. Patent No. 4,059,686 describes a pharmaceutical preparation for oral cavity administration characterized by being a mixture of a pharmacologically active agent, a pharmaceutical carrier, and sodium polyacrylate in conventional dosage form. It adheres strongly to a local site and dissolves gradually over a prolonged period of time, releasing appropriate amounts of the active agent.
The preparation is designed to adhere to mucosal membranes.
U.S. Patent No. 4,876,092 describes a sheet-shaped adhesive preparation comprising an adhesive layer containing, as essential components, a carboxyvinyl polymer, a water-insoluble methacrylic copolymer, a polyhydric alcohol, and a pharmaceutically active agent, and a water-impermeable and water-insoluble carrier layer containing, as essential components, a pharmaceutically active, water-insoluble, film-forming high molecular weight compound and a plasticizes, which can adhere within the oral cavity over a period of time and release an active agent.
The preparation is designed to be adhered to the mucous membrane.
U.S. Patent No. 3,972,995 describes a dosage form for buccal administration of a drug, and which is directly applicable to the interior surfaces of the mouth. The dosage form is comprised of a support member which is water-insoluble, waterproof and flexible, a moisture-activated adhesive precursor applied to one surface of the support member, and an active ingredient applied to the central portion of the support member, either directly or dispersed in a matrix.
The dosage form is applied directly to the interior surface of the mouth.
Contact with saliva activates the adhesive and causes the support member to adhere to the interior surface of the mouth, thereby exposing the active ingredient to a limited area of the oral mucosa while isolating the active ingredient from the remainder of the oral environment.
U.S. Patent No. 5,330,761 describes a controlled release bioadhesive tablet which includes a locally active agent, a heterodisperse gum matrix, and a pharmaceutically acceptable diluent. The final product adheres to mucous membranes and releases the locally active agent over a desired period of time.
_7_ Nagai, T., et al. (J. Cont. Rel. 6:353 (1987)) describes a sustained-release tablet capable of sticking tightly to human gingiva and not the cheek mucosa.
Further described is a self administered plaster with a water-impermeable backing layer (film).
S U.S. Patent No. 4,772,470 discloses an oral bandage comprising a soft adhesive film comprising a mixture of polycarboxylic acid and/or a polycarboxylic acid anhydride and a vinyl acetate polymer in a compatible state, and an oral preparation comprising such an oral bandage having incorporated therein a topical drug. The oral bandage or preparation is reported to exhibit strong adhesion of long duration when applied to the oral mucosa or teeth. This patent purports to teach a composition for topical administration of pharmaceutically active agents.
It is drawn primarily to the use of anesthetic compositions, but may comprise other agents as well. The composition comprises the active agent in a pharmaceutically acceptable solvent, and in an admixture also includes a bioadhesive.
U.S. Patent No. 4,900,554 describes an adhesive device for application to body tissue having an adhesive layer and a backing layer positioned over one side of the adhesive layer. The adhesive layer includes one or more acrylic acid polymers having adhesive properties upon dissolution or swelling in water and at least one water-insoluble cellulose derivative. The backing layer is water-insoluble or sparingly water-soluble. This patent discloses a composition comprising the active agent in an admixture that also includes a bioadhesive. Further, it includes a backing layer so that the adhesive does not adhere to adjacent areas.
U.S. Patent No. 5,446,070 relates to compositions and methods for topical administration of pharmaceutically active compounds and specifically to anesthetic compounds for topical administration. The invention is a flexible bioadhesive composition for topical administration. The invention is a flexible bioadhesive composition for topical application comprising a pharmaceutically active agent, a solvent and a plasticizer, in admixture with a polysaccharide bioadhesive carrier, wherein the composition is substantially free of water, substantially water-_g_ insoluble, and wherein the pharmaceutically active agent is present in a non-crystallized form. The patent discloses that an exceptionally high loading of anesthetic agents can be added to a Garner without loss of the adhesive properties, so that more rapid delivery of an anesthetic agent to a tissue without substantial crystallization of the agent can occur. The document discloses the use of the composition for topical administration to hard tissue such as teeth.
European Patent Application 223 245 discloses a curable composition containing methacrylate monomers and a polymerization initiator for application to teeth and having the property of in situ polymerization to form a hardened filler.
The document discloses the use of such filler in combination with an active agent, thereby releasing the active agent from the hardened filler.
Furthermore, each of the above-cited references further discuss sustained-release compositions, many of which can be used to release a pharmaceutically active agent in the oral cavity.
Several problems are associated with controlled-release or sustained-release formulations in the oral cavity.
A major problem is providing prolonged release at effective concentrations. For example, fungal infections beginning in the mouth and then entering other parts of the body are life-threatening to immuno-compromised patients. It is thus desirable to release antifungal agents on an ongoing basis.
However, it is very difficult to achieve.
Buccal tablets and sublingual tablets are pharmaceutical preparations primarily intended for systemic effect. These tablets are placed between the cheek and gingival or under the tongue and allowed to dissolve slowly. The drugs absorbed through the oral mucous membrane enter directly, not through the portal circulation but through the systemic circulation. An advantage of these tablets is in the efficient absorption of the drug, because the drug is not decomposed by the liver. However, if the disintegration and dissolution of the tablet are too rapid, the object of this method of administration is not achieved.
WO 99/04764 ~ PCT/US98/15096 A problem with these sustained-release devices involves the area of comfort. Patients often reject these oral sustained-release devices because they have a "foreign" feeling. As a result, these devices are often dislodged by the patient.
Recently, a tablet for stomatitis has been developed which is applicable directly to the affected region. But this preparation is also hard and has a certain thickness, and persons using it are aware of its presence. Accordingly, the tablet may be dislodged with the tongue and swallowed during eating and drinking.
Therefore, it is difficult to retain within the oral cavity for a long time.
Moreover, the known preparations are usually composed of components which are soluble or disintegrable within the mouth. Thus, the pharmaceutically active agents contained in the preparations are mostly swallowed without being absorbed through the mucous membrane in the oral cavity. Thus, these preparations are not completely satisfactory as a sustained- or controlled-release I 5 preparation for the oral cavity.
In order to retard disintegration of the above said preparations, the following trials have been made without successful results as a preparation for oral cavity administration:
1. to add larger amounts of a binder, without employing a disintegrant, such as starch;
2. to add a large amount of hydrophobic lubricant, such as magnesium stearate;
3. to coat the tablet with a water-repellent substance such as wax or paraffin.
Ointments are not satisfactory for oral cavity administration because of insufficient adhesion and rather high solubility.
Mucosal patches, which demonstrate good adhesion for extended periods of time, cause adverse reactions like mucosal itching and irritation at the patch sites or even necrosis in severe cases. (Contact-Dermatitis 25(4):230-6 (1991);
Maturitas 13(2):151-4 {1991).) In addition to health complications, the side WO 99/04764 ~ PCT/US98/15096 effects profile of a product can lead to added therapeutic costs by requiring treatment by physicians or visits to emergency rooms.
Another problem is localized release to teeth. That is, the application of agents that are designed to be delivered to teeth, for example, tooth whiteners and desensitizing agents, are for the most part wasted because delivery is to the whole oral cavity and not local to the tooth.
Another problem is the difficulty of application of sustained release devices for the oral cavity.
A particular problem involves the difficulty of obtaining prolonged release of highly soluble drugs when the delivery system is in an aqueous environment such as the oral cavity. Hydrogel systems release the drug too quickly.
Erosive systems, for example systems using the polymer EudragitTM, also result in release that is undesirably rapid.
Accordingly, there is a need for an oral controlled-release pharmaceutical delivery device with the following characteristics. Release can be sustained at desired concentrations for a desired period of time, and particularly for highly soluble drugs when the delivery system is in an aqueous environment such as the oral cavity. Necrosis is avoided. Release can be localized to teeth.
Application is easy and uncomplicated. Patient comfort is provided. The device does not impart a "foreign" feeling to the oral cavity. The device facilitates buccai absorption, resulting in rapid systemic delivery of the released agent. The device can also provide localized treatment of the oral mucosa.
Summary of the Invention The invention is broadly directed to a liquid composition comprising a polymer and tannic acid or tannin, which composition either dries to form a solid composition capable of controlled release of a pharmaceutical, or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of a pharmaceutical.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin, where the liquid composition dries to form an adhesive solid composition capable of .controlled release of a pharmaceutical or forms a precipitate that can dry to form an adhesive solid composition capable of controlled release of a pharmaceutical.
The invention further encompasses liquid compositions comprising a polymer and tannic acid or tannin and a pharmaceutical, where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical, where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical, or forms a precipitate that dries to form an adhesive solid composition capable of controlled release of the pharmaceutical.
The invention further encompasses a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical, wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical wherein the pharmaceutical agent is entrapped in Iiposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form an adhesive solid composition capable of controlled release ofthe pharmaceutical.
The invention naturally encompasses solid compositions comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical. -_ In preferred embodiments, the invention is directed to a solid adhesive composition comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
In alternative embodiments, the polymer is a cellulosic polymer. Preferred polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
The invention is also directed to methods of making each of the compositions disclosed herein.
The invention is also directed to the use of the solid compositions in the treatment of various conditions, or in uses where controlled release of an agent is desirable.
In preferred embodiments, the invention is directed to a composition for sustained release of a pharmaceutical in the oral cavity.
In a highly preferred form, the invention is in the form of a pharmaceutical oral patch that can be attached to the surface of a tooth or other hard dental structure where it can release an agent for topical, systemic, or local treatment.
Brief Description of the Figures Figure 1: In vitro release of nicotine from patches containing nicotine entrapped in liposomes compared to patches containing nicotine not entrapped in liposomes. Figure 1 shows the average release of nicotine from Patches # 285-(I, II), 285-23B (III, IV), 285-28(V) containing centrifuged liposomes Type MLV, and comparison to nicotine release from non-liposomal nicotine Patches #
49A00 (VI,VIII). The filled circle is I-II; the filled square is III-IV; the open triangle is V, and the filled triangle is VI-VIII.
Figure 2: In vivo release of nicotine from patches containing nicotine entrapped in liposomes compared to patches containing nicotine not entrapped in liposomes. Figure 2 shows release of nicotine from patch # 285-28 containing centrifuged liposomes Type MLV compared to nicotine release from non-liposomal Patch #158-64. The solid circle is #285-28 and the solid box is #158-64.
Figure 3: In vitro release of flurbiprofen from patch.
Detailed Description of the Preferred Embodiments The invention is broadly directed to a liquid composition comprising a polymer and tannic acid or tannin, which composition either dries to form a solid composition capable of controlled release of a pharmaceutical, or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of a pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
In alternative embodiments, the polymer is a cellulosic polymer. Preferred polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments of the invention, the liquid composition comprises a mixture of the polymer and tannic acid or tannin.
The minimal essential components of the liquid composition can be a polymer and tannic acid or tannin. It is understood, however, that the liquid composition may contain more than one polymer. Thus, the composition can encompass more than one protein, more than one cellulosic polymer, and combinations of the two.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin.
Optional components include plasticizers, such as glycerol, polyethylene glycols, and citrate esters, glycerol being a particularly preferred plasticizes when the polymer is a hydrolyzed gelatin.
However, glycerol may also be used as a plasticizes with other proteins described herein or in general embodiments in which a protein is used in combination with tannic acid or tannin.
Emulsifiers may also be added, optionally.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin, where the liquid composition dries to form an adhesive solid composition capable of controlled release of a pharmaceutical or forms a precipitate that can dry to form an adhesive solid composition capable of controlled release of a pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen and albumin.
In alternative embodiments, the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments, the liquid composition comprises a mixture of the polymer and tannic acid or tannin.
The minimal essential components in the liquid composition can be the polymer and tannic acid or tannin. It is understood, however, that the liquid composition may contain more than one polymer. Thus, the composition encompasses more than one protein, more than one cellulosic polymer, and combinations of the two.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin.
Other components are optionally included. These include plasticizers, such as glycerol, polyethylene glycols and citrate esters, with glycerol being the particularly preferred plasticizer when the polymer is a hydrolyzed gelatin.
Emulsifiers may also be added optionally.
S The invention further encompasses liquid compositions comprising a polymer and tannic acid and tannin and a pharmaceutical, where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen and albumin.
In alternative embodiments, the polymer is a cellulosic polymer and tannic acid or tannin and a pharmaceutical. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments, the liquid composition comprises a mixture of the polymer, tannic acid or tannin, and a pharmaceutical.
The minimal essential components of the liquid composition can be, therefore, a polymer, tannic acid or tannin, and the pharmaceutical. However, it is to be understood that more than one polymer or type of polymer can be included. That is, more than one protein, more than one cellulosic polymer, and combinations of the two, are encompassed.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical.
Optional agents include plasticizers such as glycerol, polyethylene glycols and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is a protein, and particularly hydrolyzed gelatin.
Emulsifiers may also be added optionally.
WO 99/04764 PCTlUS98/15096 In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical, where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical, or forms a precipitate that dries to form an adhesive solid composition capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen and albumin.
Alternatively, the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments, the liquid composition comprises a mixture of the polymer and tannic acid or tannin and the pharmaceutical.
The minimal essential components for forming the adhesive solid composition can be the polymer, tannic acid or tannin, and a pharmaceutical.
It is understood, however, that the liquid composition may contain more than one polymer or type of polymer. Thus, the composition encompasses mixtures of various proteins, cellulosic polymers, and combinations of the two.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical.
Optional components include plasticizers such as glycerol, polyethylene glycols and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is hydrolyzed gelatin.
Emulsifiers may also be added optionally.
The invention further encompasses liquid compositions comprising a polymer and tannic acid or tannin and a pharmaceutical, wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
Also for this aspect of the invention in which the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres, in preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen, and albumin.
The liposome may be a multilamellar vesicle or unilamellar vesicle.
Liposomes comprise phospholipids and/or sphingolipids and optionally lipids such as cholesterol and phosphatidic acid and antioxidants. Preferred phospholipids are soybean lecithin, egg lecithin, soybean phosphatidylcholine, egg phosphatidylcholine, synthetic phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidylethanolamine, alone or in mixtures. A preferred sphingolipid is sphingomyelin. Highly preferred liposomes comprise phosphatidylcholine, phosphatidylethanolamine, cholesterol and an antioxidant.
The microcapsule, microsphere, nanocapsule or nanosphere comprises polymers and optionally plasticizers and emulsifiers. The preferred polymers comprising these microcapsules, microspheres, nanocapsules or nanospheres are polyalkyl methacrylate such as polymethylmethacrylate, polyalkylcyanoacrylates such as polymethylcyanomethacrylate, polyesters such as polylactic acid and polylactic/glycolic acid copolymers, cellulose derivatives such as ethylcellulose and cellulose acetate and proteins such as albumin, gelatin, and hydrolyzed gelatin, and polysaccharides such as sodium alginate, pectin, chitosan, guar gum, and xanthan gum.
In alternate embodiments of the liquid composition of the invention the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred such embodiments, the liquid composition comprises a mixture of the polymer, tannic acid or tannin, and a pharmaceutical entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres.
The minimal essential components of the liquid composition can be, therefore, a polymer, tannic acid or tannin, and the pharmaceutical entrapped in a liposome or microcapsule, microsphere, nanocapsule or nanosphere. However, it is to be understood that more than one polymer or type of polymer can be included. That is, more than one protein, more than one cellulosic polymer, and combinations of the two, are encompassed. It is further understood that more than one type of liposome or microcapsule, microsphere, nanocapsule or nanosphere or combination of any of them, are also encompassed.
Thus the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical entrapped 1 S in any of the liposomes or microcapsules, microspheres, nanocapsules or nanospheres, or combination of liposomes or microcapsules, microspheres, nanocapsules or nanospheres as disclosed herein.
Optional agents include plasticizers such as glycerol, polyethylene glycols, and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is a protein, and particularly hydrolyzed gelatin.
Emulsifiers may also be added optionally.
In highly preferred embodiments, also for this additional aspect of the invention in which the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres, the invention is directed to liquid compositions comprising a polymer and tannic acid or tannin and a pharmaceutical wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being *rB
dried to form an adhesive solid composition capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen, and albumin.
The liposomes may be a multilamellar vesicle or a unilamellar vesicle.
Liposomes comprise phospholipids and/or sphingolipids and optionally lipids such as cholesterol and phosphatidic acid and antioxidants. Preferred phospholipids are soybean lecithin, egg lecithin, soybean phosphatidylcholine, egg phosphatidylcholine, synthetic phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidylethanolamine, alone or in mixtures. A preferred sphingolipid is sphingomyelin. Highly preferred liposomes comprise phosphatidylcholine, phosphatidylethanolamine, cholesterol and an antioxidant.
The microcapsule, microsphere, nanocapsule or nanosphere comprises polymers and optionally plasticizers and emulsifiers. The preferred polymers comprising these or microcapsules, microspheres, nanocapsules or nanospheres are polyalkyl methacrylate such as polymethylmethacrylate, polyalkylcyanoacrylates such as polymethylcyanomethacrylate, polyesters such as polylactic acid and polylactic/glycolic acid copolymers, cellulose derivatives such as ethylcellulose and cellulose acetate and proteins such as albumin, gelatin, and hydrolyzed gelatin, and polysaccharides such as sodium alginate, pectin, chitosan, guar gum, and xanthan gum.
In alternate embodiments of the liquid composition of the invention the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In such preferred embodiments, the liquid composition comprises a mixture of the polymer, tannic acid or tannin, and a pharmaceutical entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres.
The minimal essential components of the liquid composition can be, therefore, a polymer, tannic acid or tannin, and the pharmaceutical entrapped in a liposome or microcapsule, microsphere, nanocapsule or nanosphere. -However, it is to be understood that more than one polymer or type of polymer can be included. That is, more than one protein, more than one cellulosic polymer, and combinations of any of them, are encompassed. It is further understood that more than one type of liposome or microcapsule, microsphere, nanocapsule or nanosphere or combination of the two, are also encompassed.
Thus the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical entrapped in any of the liposomes or microcapsules, microspheres, nanocapsules or nanospheres, or combination of liposomes or microcapsules, microspheres, nanocapsules or nanospheres as disclosed herein.
Optional agents include plasticizers such as glycerol, polyethylene glycols, and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is a protein, and particularly hydrolyzed gelatin.
Emulsifiers may also be added optionally.
The invention naturally encompasses solid compositions comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
Alternatively, the polymer is a cellulosic polymer. Preferred polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
Since the liquid composition can comprise a mixture of the polymer, tannic acid or tannin and the pharmaceutical, the solid composition accordingly comprises a mixture of a polymer, tannic acid or tannin, and a pharmaceutical.
WO 99!04764 PCT/US98115096 Thus, the pharmaceutical is dispersed or embedded in the dried matrix of the polymer-tannic acid/tannin.
The minimal essential components in the solid composition can include the polymer, tannic acid or tannin, and a pharmaceutical. It is understood, however, that the solid composition may contain more than one suitable polymer. Thus, the composition encompasses more than one protein, more than one cellulosic polymer, and combinations of the two.
Thus, the solid composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin and the pharmaceutical.
When appropriate, the solid composition of this invention may be coated with a suitable pharmaceutical coating.
In preferred embodiments, the invention is directed to a solid adhesive composition comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
Alternatively, the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
The solid adhesive composition comprises a mixture of a polymer, tannic acid or tannin and a pharmaceutical.
Thus, the pharmaceutical is dispersed or embedded in the dried adhesive matrix of the polymer-tannic acid/tannin.
The minimal essential components in the solid adhesive composition can be the polymer, tannic acid or tannin, and the pharmaceutical. It is understood, however, that the solid composition may contain more than one polymer. Thus, the composition encompasses more than one protein, more than one cellulosic polymer, and combinations of the two.
Accordingly, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, combinations thereof, as well as other appropriate polymers, and tannic acid or tannin, and a pharmaceutical.
The solid compositions described herein encompass biodegradable formulations.
Although the above description relates specifically to the release of pharmaceuticals, it is to be understood that other agents can be released from the solid compositions described herein. Examples of such agents include, but are not limited to, cosmetics, vitamins, minerals, flavorants, colorants, toxins such as pesticides, odorants, and the like.
For controlling the release of a pharmaceutical or other agent from the solid compositions disclosed herein, the agent can be entrapped in the polymeraannic acid matrix. The extent of such entrapment, and thereby the extent of sustained release, is controlled by the choice of polymer.
The solvents used to prepare the polymer-tannic complex can be useful as release-adjusting agents, since they can strongly affect the release rate, as shown in the examples herein.
An outer polymer matrix as shown in the examples herein, is a form of release-adjusting agent because it contributes to controlling the release of the drug. It can be formulated with or without its own release-adjusting agents, to retard release from the inner matrix by varying amounts.
Release of the pharmaceutical can also be controlled by the addition of pH-adjusting agents, release-adjusting agents, solubility-adjusting agents, and combinations thereof, to the solution or suspension of the polymer being added to the dried precipitate.
The invention is also directed to methods of making each of the compositions disclosed herein.
In its broadest embodiment, the polymer and tannic acid or tannin are mixed in a solvent, and the mixture is then dried to form the solid composition.
Alternatively, the polymer may be first dissolved in a solvent and the tannic acid or tannin separately dissolved in a solvent prior to mixing.
The polymer may or may not form a precipitate when mixed with the tannic acid or tannin. In embodiments in which the tannic acid or tannin forms a precipitate with the polymer, the composition is made as follows:
(1) the polymer is dissolved in a solvent, (2) tannic acid or tannin is added in a solvent, {3) a precipitate is allowed to form, (4) the precipitate is dried to form the solid composition.
A pharmaceuticals) can be added to the polymer solution or the tannic acid solution. When added to a polymer solution which will form a precipitate, the pharmaceutical is then mixed in the precipitate that is formed, so that when the precipitate is dried the pharmaceutical is embedded or dispersed in the solid composition formed from the precipitate.
In alternative embodiments, however, the solid composition can be formed as in steps 1-4 and then one or more pharmaceuticals can be added to this precipitate that is further processed for controlled release of the pharmaceuticals j from the dried precipitate. The drug can be added to the dried precipitate in solution and then subsequently dried or can be mixed in powdered form with the precipitate. This can then be pressed or otherwise formed together according to methods well known in the art.
Preferred solvents for the polymer include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
Preferred solvents for the tannic acid or tannin include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
When the polymer is a protein, preferred solvents include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
When the polymer is a cellulosic polymer, preferred solvents include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
When the polymer and tannic acid are dissolved in the same solvent, preferred solvents include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
In alternative embodiments, the dried precipitate disclosed above is ground into a powder, and the powder is then mixed with a further polymer in a solvent, and this mixture is then dried to form the final solid composition. This second polymer thus forms an outer matrix over the complex.
Preferred polymers for mixing with the polymer-tannic acid/tannin precipitate include any polymer that physically binds the powder together, allowing the powder to adhere to the tooth as a mass. The polymer needs to be flexible, and therefore, a plasticizer is essential. The polymer should be degradable and/or allow saliva to diffuse through it to allow for drug release from the powder.
The polymer should be either soluble or dispersible in a solvent in which the powder is insoluble, so that the powder will not re-dissolve when the polymer is added.
This second polymer can optionally be formulated with release-adjusting agents, pH-adjusting agents, emulsifiers, and solubility-adjusting agents.
The preferred second polymer is a polyacrylate polymer, and particularly a EudragitTM polymer.
Preferred polymers that can be used as a second polymer when the first polymer is a protein or a cellulosic polymer include, but are not limited to, EudragitTM L-100, EudragitTM L 30D-55, EudragitTM S-100, EudragitTM NE-100, EudragitTM NE-30, EudragitTM RL, EudragitTM RS, hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, pectin, calcium pectinate, *rB
WO 99/04764 ~ PCT/US98/15096 alginic acid, calcium alginate, cellulose acetate phthalate, carbopol, guar gum, gum tragacanth, gum acacia, other vegetable gums, and chitosan.
The second polymer serves as a matrix for the tannic-polymer-complex powder (precipitate). It binds the powder together for ease of application and control of dosage. That is, a premeasured amount of the pharmaceutical agents) can be applied in one single application, rather than in repeated applications (as in a varnish coated onto teeth, for example).
It further can help control the rate of releasing the drug by controlling or attenuating the ability of the saliva to interact with the precipitate. The degradation of the polymer and permeability with saliva allow for the release of the powder into the saliva and thereby for the release of the pharmaceutical.
In preferred embodiments, the composition is made as follows: ( 1 ) protein and a pharmaceutical are dissolved in a solvent comprising ethanol and water;
(2) tannic acid or tannin is added in a solvent comprising ethanol and water;
(3) a precipitate is allowed to form; (4) the precipitate is dried to form the solid composition.
In highly preferred embodiments, the first four steps above are performed but the following additional steps are then performed: (S) the dried precipitate is ground into a powder; (6) the powder is mixed with a EudragitTM polymer and a plasticizer in a solvent comprising ethanol and water or as a latex suspension in water; (7) the mixture is dried.
In highly-preferred embodiments of the invention, the protein is hydrolyzed gelatin and the second polymer is EudragitTM L-100.
Preferred pharmaceuticals include, but are not limited to, nicotine, nicotine salts, nicotine polymer complexes, lidocaine, piroxicam, flurbiprofen, dihydroergotamine mesylate, ergotamine tartarate, sumaptriptan succinate, isosorbide dinitrate, isosorbide mononitrate, nifedipine, ondansetron hydrochloride, and peptide drugs. Highly or significantly water-soluble pharmaceuticals are particularly suited for release from embodiments in which a protein-tannic acid/tannin precipitate has been formed. Embodiments including a second polymer are particularly suitable for releasing such pharmaceuticals.
In certain embodiments of the invention, the same or a-_ different pharmaceutical can be added in the second polymer solution and be released therefrom (when solidified).
The invention is also directed to the use of the solid compositions in the treatment of various conditions. The compositions can also be used as a powder or microcapsule in a capsule for oral delivery to the gastrointestinal tract, compressed into tablets alone or with typical excipients for oral delivery to the gastrointestinal tract, as a lozenge for local delivery to the oral cavity or for delivery to the gastrointestinal tract, a suppository for rectal delivery, a vaginal tablet or suppository, or as an ointment for topical use.
Accordingly, depending on the use of the compositions, the physical form of the composition can be adjusted. For example, the compositions may be used as a film, nanoparticle, microparticle or bead. The compositions could also be used as a powder or microcapsules in a capsule, compressed into tablets alone or with typical excipients, as a lozenge, suppository, vaginal tablet or suppository, or as an ointment. When appropriate, the composition of this invention may be coated with a suitable pharmaceutical coating.
In preferred embodiments, the invention is directed to a composition for sustained release of a pharmaceutical in the oral cavity. In a highly preferred form, the invention is in the form of a pharmaceutical oral patch that can be attached to the surface of a tooth, denture, or other hard dental structure.
The method provides for buccal absorption of an active agent resulting in rapid systemic delivery of desired amounts of agent for a desired period of time.
The method also provides for the delivery of an active agent confined to a tooth area and avoiding release elsewhere in the oral cavity.
The method also allows for localized treatment of affected sites in the oral cavity or throat area.
_27_ The invention also provides a patient with the compositions described herein by adhesively adhering the solid, sustained-release composition to the hard surface of the patient's mouth, for example, teeth or dentures As a pharmaceutical oral patch, the solid composition can be modified into any shape and size, depending on the purposes of drug release. Thus, if large amounts of a drug are to be released, in addition to increasing the concentration of drug, in the sustained-release composition, the solid form can be larger in size and/or greater in thickness.
The important consideration for shape and size is that the patch does not confer unusual sensation to the patient when applied, and can effectively release the desired pharmaceutically active agent at the desired levels and for the desired duration of time. For example, for the rapid release of a small amount of drug, a thin layer, in which the drug is dispersed, may be required.
The following considerations are important in choosing the site of application: (1) the salivary flow around the site; (2) the accessibility for application; (3) the comfort of the patient.
Patch components are suitable to remain in the oral cavity for prolonged periods of time. In a preferred embodiment, the patch remains in the oral cavity between 6 to 8 hours. However, other embodiments can last for various desired periods of time.
The invention is also directed to a method for making the sustained-release compositions so that the rate of release can be adjusted in the final, solid form.
The invention is also directed to methods for using the compositions of the present invention to release appropriate pharmaceutical agents in the oral cavity.
Potentially, any pharmaceutically active agent can be released, although, as mentioned, the preferred agents are those that are soluble or very soluble in water.
In addition, potentially any condition can be treated by means of the release of a pharmaceutical from the patch. These are described in more detail below.
Preferred sites of application include but are not limited to the upper teeth.
WO 99!04764 PCT/US98/15096 The sites of action for the pharmaceutically active agents include the oral mucosa of the mouth, throat, and esophagus per se, systemic delivery via the oral mucosa, or localized delivery to one or more teeth.
The amount of active agent included in the final, controlled release product S can be determined by one skilled in the art without undue experimentation, and is generally from about 0.1% to about 35% by weight of the final product. The particular amount of the active agent included will, of course, depend upon the particular agent and its intended use.
The present invention can include other locally active agents, such as flavorants and sweeteners. The flavoring agents may be natural or synthetic.
The flavoring agent is a common flavorant including wintergreen, peppermint, spearmint, menthol, fruit flavors, vanilla, cinnamon, various spices, or others known in the art. Generally any flavoring or food additive, such as those described in Chemical Used in Food Processing, Pub. No. 1274, National Academy of Sciences, pages 63-258, can be used. The amount of flavoring employed is normally a matter of preference subject to such factors as flavor type, individual flavor, and strength desired. Generally, the final product includes from about 0.1 % to about 5% weight flavorant.
Sweeteners useful in the present invention include sucrose and aspartame.
In general, sweeteners (when present) are included in an amount from about 0.001 % to about 5.0% by weight of the final product.
Effective amounts of coloring agents (e.g., titanium dioxide, F.D. & C., and D. & C. dyes; see the Kirk-Othmer Encyclopedia of Chemical Technology, vol. 5, pp. 857-884); softeners, stabilizers, binders, odor-controlling agents, and preservatives can also be contained in the patch, as long as they do not impair adhesiveness or impede pharmacological effects.
The term "therapeutically effective amount" is intended to mean the amount of pharmaceutically active agent sufficient to produce the desired effect when released from the dental patch described herein. These amounts are known in the art or may be determined by methods known in the art. The amounts depend upon the agents chosen and whether the site of action is the tooth per se, the oral mucosa (and the region of the oral mucosa), or systemic.
The upper limit on the amount of drug in the composition is determined by the properties of the polymeric matrix and the chemical interaction of the drug with the polymeric matrix.
The amount of active agent in the composition necessary to provide the desired amounts and concentration in the oral cavity can be determined by known methods. Thus, the concentration and the quantity of the agent per unit area of the patch (i.e., per square or cubic millimeter) can be varied independently in order to achieve a desired effect. Higher concentrations of agent contained in a dosage form of decreased thickness will result in an agent with fast onset and short duration. High concentrations of an agent contained in a dosage form of increased thickness (higher milligrams of agent per square or cubic millimeter) will result in potent effect with fast onset and long duration. Low concentrations of the agent in a dosage form of decreased thickness will result in mild effect with longer onset and short duration. Low concentrations of the agent contained in a dosage form of increased thickness will have mild effect with longer onset and longer duration.
As shown in the above explanation, the ability to coat thin or thick, enables the practitioner of the invention to vary the dosage of the system as needed for particular anatomical sites of interest and according to the specific drug.
The term "onset" is intended to mean the time needed to reach the desired concentration level of the pharmaceutical agent. It is used according to its normal and art-recognized meaning.
The term "duration" as used herein, means the period of time during which the desired concentration of pharmaceutical agent is delivered. This term is used according to its normal and art-recognized meaning.
The term "adhesive" as used herein, means an adhesive which attaches, and preferably strongly attaches, the release layer to teeth or other hard structures in the mouth such as dentures. To qualify as an adhesive, the substance must be capable of maintaining adhesion in the moist or wet environments of the oral cavity. It can also be "self adhesive" in that it attaches to the site of interest without the need to reinforce its attachment by way of another adhesive. Thus, the term "adhesive" is used according to its normal and art-recognized meaning.
Adhesion can only be quantified with reference to a specific type of test or S usage. It is not in itself a basic physical property, such as the surface free energy or the film thickness, whose measurement can be accomplished by a variety of methods. "Adhesion performance" must therefore be defined and measured in the context of the application of interest. Whether a given adhesive is effective for the oral cavity can be determined by a peel test in artificial saliva.
1 U The strength of adherence can be measured by standard tests for measuring the force, for example in dynes per square centimeter, as disclosed in U.S.
Patent No. 4,615,697.
The term "subject" or "patient" is intended to include all mammals, preferably humans.
15 The term "patch", as used herein, is intended to mean a three-dimensional solid composition that can be adhered to teeth, or other hard structures in the mouth, such as dentures, which can contain a pharmaceutically active agent, and which can release the pharmaceutically active agent in effective amounts, for a desired period of time, from its site of attachment within the oral cavity.
20 By "pharmaceutically active agent" is intended any chemical or biochemical that can be released from the dental patch to prevent, cure, or ameliorate an undesirable physiological condition (see below). The term "drug" is used interchangeably herein. These terms are used according to their normal and art-recognized meanings.
25 Although any agent can be used, depending on the purpose of therapy, the following are exemplary:
1. anti-inflammatory, analgesic agents: content 0.1-5%
2. steroidal anti-inflammatory agents: content 0.002-0.5%
3. antihistamines:0.l-2%
30 4. local anesthetics: 0.05-2%
5. bacteriocides and disinfectants: 0.01-10%
6. vasoconstrictors: 0.01-1
The preparation is designed to adhere to mucosal membranes.
U.S. Patent No. 4,876,092 describes a sheet-shaped adhesive preparation comprising an adhesive layer containing, as essential components, a carboxyvinyl polymer, a water-insoluble methacrylic copolymer, a polyhydric alcohol, and a pharmaceutically active agent, and a water-impermeable and water-insoluble carrier layer containing, as essential components, a pharmaceutically active, water-insoluble, film-forming high molecular weight compound and a plasticizes, which can adhere within the oral cavity over a period of time and release an active agent.
The preparation is designed to be adhered to the mucous membrane.
U.S. Patent No. 3,972,995 describes a dosage form for buccal administration of a drug, and which is directly applicable to the interior surfaces of the mouth. The dosage form is comprised of a support member which is water-insoluble, waterproof and flexible, a moisture-activated adhesive precursor applied to one surface of the support member, and an active ingredient applied to the central portion of the support member, either directly or dispersed in a matrix.
The dosage form is applied directly to the interior surface of the mouth.
Contact with saliva activates the adhesive and causes the support member to adhere to the interior surface of the mouth, thereby exposing the active ingredient to a limited area of the oral mucosa while isolating the active ingredient from the remainder of the oral environment.
U.S. Patent No. 5,330,761 describes a controlled release bioadhesive tablet which includes a locally active agent, a heterodisperse gum matrix, and a pharmaceutically acceptable diluent. The final product adheres to mucous membranes and releases the locally active agent over a desired period of time.
_7_ Nagai, T., et al. (J. Cont. Rel. 6:353 (1987)) describes a sustained-release tablet capable of sticking tightly to human gingiva and not the cheek mucosa.
Further described is a self administered plaster with a water-impermeable backing layer (film).
S U.S. Patent No. 4,772,470 discloses an oral bandage comprising a soft adhesive film comprising a mixture of polycarboxylic acid and/or a polycarboxylic acid anhydride and a vinyl acetate polymer in a compatible state, and an oral preparation comprising such an oral bandage having incorporated therein a topical drug. The oral bandage or preparation is reported to exhibit strong adhesion of long duration when applied to the oral mucosa or teeth. This patent purports to teach a composition for topical administration of pharmaceutically active agents.
It is drawn primarily to the use of anesthetic compositions, but may comprise other agents as well. The composition comprises the active agent in a pharmaceutically acceptable solvent, and in an admixture also includes a bioadhesive.
U.S. Patent No. 4,900,554 describes an adhesive device for application to body tissue having an adhesive layer and a backing layer positioned over one side of the adhesive layer. The adhesive layer includes one or more acrylic acid polymers having adhesive properties upon dissolution or swelling in water and at least one water-insoluble cellulose derivative. The backing layer is water-insoluble or sparingly water-soluble. This patent discloses a composition comprising the active agent in an admixture that also includes a bioadhesive. Further, it includes a backing layer so that the adhesive does not adhere to adjacent areas.
U.S. Patent No. 5,446,070 relates to compositions and methods for topical administration of pharmaceutically active compounds and specifically to anesthetic compounds for topical administration. The invention is a flexible bioadhesive composition for topical administration. The invention is a flexible bioadhesive composition for topical application comprising a pharmaceutically active agent, a solvent and a plasticizer, in admixture with a polysaccharide bioadhesive carrier, wherein the composition is substantially free of water, substantially water-_g_ insoluble, and wherein the pharmaceutically active agent is present in a non-crystallized form. The patent discloses that an exceptionally high loading of anesthetic agents can be added to a Garner without loss of the adhesive properties, so that more rapid delivery of an anesthetic agent to a tissue without substantial crystallization of the agent can occur. The document discloses the use of the composition for topical administration to hard tissue such as teeth.
European Patent Application 223 245 discloses a curable composition containing methacrylate monomers and a polymerization initiator for application to teeth and having the property of in situ polymerization to form a hardened filler.
The document discloses the use of such filler in combination with an active agent, thereby releasing the active agent from the hardened filler.
Furthermore, each of the above-cited references further discuss sustained-release compositions, many of which can be used to release a pharmaceutically active agent in the oral cavity.
Several problems are associated with controlled-release or sustained-release formulations in the oral cavity.
A major problem is providing prolonged release at effective concentrations. For example, fungal infections beginning in the mouth and then entering other parts of the body are life-threatening to immuno-compromised patients. It is thus desirable to release antifungal agents on an ongoing basis.
However, it is very difficult to achieve.
Buccal tablets and sublingual tablets are pharmaceutical preparations primarily intended for systemic effect. These tablets are placed between the cheek and gingival or under the tongue and allowed to dissolve slowly. The drugs absorbed through the oral mucous membrane enter directly, not through the portal circulation but through the systemic circulation. An advantage of these tablets is in the efficient absorption of the drug, because the drug is not decomposed by the liver. However, if the disintegration and dissolution of the tablet are too rapid, the object of this method of administration is not achieved.
WO 99/04764 ~ PCT/US98/15096 A problem with these sustained-release devices involves the area of comfort. Patients often reject these oral sustained-release devices because they have a "foreign" feeling. As a result, these devices are often dislodged by the patient.
Recently, a tablet for stomatitis has been developed which is applicable directly to the affected region. But this preparation is also hard and has a certain thickness, and persons using it are aware of its presence. Accordingly, the tablet may be dislodged with the tongue and swallowed during eating and drinking.
Therefore, it is difficult to retain within the oral cavity for a long time.
Moreover, the known preparations are usually composed of components which are soluble or disintegrable within the mouth. Thus, the pharmaceutically active agents contained in the preparations are mostly swallowed without being absorbed through the mucous membrane in the oral cavity. Thus, these preparations are not completely satisfactory as a sustained- or controlled-release I 5 preparation for the oral cavity.
In order to retard disintegration of the above said preparations, the following trials have been made without successful results as a preparation for oral cavity administration:
1. to add larger amounts of a binder, without employing a disintegrant, such as starch;
2. to add a large amount of hydrophobic lubricant, such as magnesium stearate;
3. to coat the tablet with a water-repellent substance such as wax or paraffin.
Ointments are not satisfactory for oral cavity administration because of insufficient adhesion and rather high solubility.
Mucosal patches, which demonstrate good adhesion for extended periods of time, cause adverse reactions like mucosal itching and irritation at the patch sites or even necrosis in severe cases. (Contact-Dermatitis 25(4):230-6 (1991);
Maturitas 13(2):151-4 {1991).) In addition to health complications, the side WO 99/04764 ~ PCT/US98/15096 effects profile of a product can lead to added therapeutic costs by requiring treatment by physicians or visits to emergency rooms.
Another problem is localized release to teeth. That is, the application of agents that are designed to be delivered to teeth, for example, tooth whiteners and desensitizing agents, are for the most part wasted because delivery is to the whole oral cavity and not local to the tooth.
Another problem is the difficulty of application of sustained release devices for the oral cavity.
A particular problem involves the difficulty of obtaining prolonged release of highly soluble drugs when the delivery system is in an aqueous environment such as the oral cavity. Hydrogel systems release the drug too quickly.
Erosive systems, for example systems using the polymer EudragitTM, also result in release that is undesirably rapid.
Accordingly, there is a need for an oral controlled-release pharmaceutical delivery device with the following characteristics. Release can be sustained at desired concentrations for a desired period of time, and particularly for highly soluble drugs when the delivery system is in an aqueous environment such as the oral cavity. Necrosis is avoided. Release can be localized to teeth.
Application is easy and uncomplicated. Patient comfort is provided. The device does not impart a "foreign" feeling to the oral cavity. The device facilitates buccai absorption, resulting in rapid systemic delivery of the released agent. The device can also provide localized treatment of the oral mucosa.
Summary of the Invention The invention is broadly directed to a liquid composition comprising a polymer and tannic acid or tannin, which composition either dries to form a solid composition capable of controlled release of a pharmaceutical, or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of a pharmaceutical.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin, where the liquid composition dries to form an adhesive solid composition capable of .controlled release of a pharmaceutical or forms a precipitate that can dry to form an adhesive solid composition capable of controlled release of a pharmaceutical.
The invention further encompasses liquid compositions comprising a polymer and tannic acid or tannin and a pharmaceutical, where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical, where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical, or forms a precipitate that dries to form an adhesive solid composition capable of controlled release of the pharmaceutical.
The invention further encompasses a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical, wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical wherein the pharmaceutical agent is entrapped in Iiposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form an adhesive solid composition capable of controlled release ofthe pharmaceutical.
The invention naturally encompasses solid compositions comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical. -_ In preferred embodiments, the invention is directed to a solid adhesive composition comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
In alternative embodiments, the polymer is a cellulosic polymer. Preferred polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
The invention is also directed to methods of making each of the compositions disclosed herein.
The invention is also directed to the use of the solid compositions in the treatment of various conditions, or in uses where controlled release of an agent is desirable.
In preferred embodiments, the invention is directed to a composition for sustained release of a pharmaceutical in the oral cavity.
In a highly preferred form, the invention is in the form of a pharmaceutical oral patch that can be attached to the surface of a tooth or other hard dental structure where it can release an agent for topical, systemic, or local treatment.
Brief Description of the Figures Figure 1: In vitro release of nicotine from patches containing nicotine entrapped in liposomes compared to patches containing nicotine not entrapped in liposomes. Figure 1 shows the average release of nicotine from Patches # 285-(I, II), 285-23B (III, IV), 285-28(V) containing centrifuged liposomes Type MLV, and comparison to nicotine release from non-liposomal nicotine Patches #
49A00 (VI,VIII). The filled circle is I-II; the filled square is III-IV; the open triangle is V, and the filled triangle is VI-VIII.
Figure 2: In vivo release of nicotine from patches containing nicotine entrapped in liposomes compared to patches containing nicotine not entrapped in liposomes. Figure 2 shows release of nicotine from patch # 285-28 containing centrifuged liposomes Type MLV compared to nicotine release from non-liposomal Patch #158-64. The solid circle is #285-28 and the solid box is #158-64.
Figure 3: In vitro release of flurbiprofen from patch.
Detailed Description of the Preferred Embodiments The invention is broadly directed to a liquid composition comprising a polymer and tannic acid or tannin, which composition either dries to form a solid composition capable of controlled release of a pharmaceutical, or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of a pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
In alternative embodiments, the polymer is a cellulosic polymer. Preferred polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments of the invention, the liquid composition comprises a mixture of the polymer and tannic acid or tannin.
The minimal essential components of the liquid composition can be a polymer and tannic acid or tannin. It is understood, however, that the liquid composition may contain more than one polymer. Thus, the composition can encompass more than one protein, more than one cellulosic polymer, and combinations of the two.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin.
Optional components include plasticizers, such as glycerol, polyethylene glycols, and citrate esters, glycerol being a particularly preferred plasticizes when the polymer is a hydrolyzed gelatin.
However, glycerol may also be used as a plasticizes with other proteins described herein or in general embodiments in which a protein is used in combination with tannic acid or tannin.
Emulsifiers may also be added, optionally.
In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin, where the liquid composition dries to form an adhesive solid composition capable of controlled release of a pharmaceutical or forms a precipitate that can dry to form an adhesive solid composition capable of controlled release of a pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen and albumin.
In alternative embodiments, the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments, the liquid composition comprises a mixture of the polymer and tannic acid or tannin.
The minimal essential components in the liquid composition can be the polymer and tannic acid or tannin. It is understood, however, that the liquid composition may contain more than one polymer. Thus, the composition encompasses more than one protein, more than one cellulosic polymer, and combinations of the two.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin.
Other components are optionally included. These include plasticizers, such as glycerol, polyethylene glycols and citrate esters, with glycerol being the particularly preferred plasticizer when the polymer is a hydrolyzed gelatin.
Emulsifiers may also be added optionally.
S The invention further encompasses liquid compositions comprising a polymer and tannic acid and tannin and a pharmaceutical, where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen and albumin.
In alternative embodiments, the polymer is a cellulosic polymer and tannic acid or tannin and a pharmaceutical. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments, the liquid composition comprises a mixture of the polymer, tannic acid or tannin, and a pharmaceutical.
The minimal essential components of the liquid composition can be, therefore, a polymer, tannic acid or tannin, and the pharmaceutical. However, it is to be understood that more than one polymer or type of polymer can be included. That is, more than one protein, more than one cellulosic polymer, and combinations of the two, are encompassed.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical.
Optional agents include plasticizers such as glycerol, polyethylene glycols and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is a protein, and particularly hydrolyzed gelatin.
Emulsifiers may also be added optionally.
WO 99/04764 PCTlUS98/15096 In highly preferred embodiments, the invention is directed to a liquid composition comprising a polymer and tannic acid or tannin and a pharmaceutical, where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical, or forms a precipitate that dries to form an adhesive solid composition capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen and albumin.
Alternatively, the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred embodiments, the liquid composition comprises a mixture of the polymer and tannic acid or tannin and the pharmaceutical.
The minimal essential components for forming the adhesive solid composition can be the polymer, tannic acid or tannin, and a pharmaceutical.
It is understood, however, that the liquid composition may contain more than one polymer or type of polymer. Thus, the composition encompasses mixtures of various proteins, cellulosic polymers, and combinations of the two.
Thus, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical.
Optional components include plasticizers such as glycerol, polyethylene glycols and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is hydrolyzed gelatin.
Emulsifiers may also be added optionally.
The invention further encompasses liquid compositions comprising a polymer and tannic acid or tannin and a pharmaceutical, wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form a solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being dried to form a solid composition capable of controlled release of the pharmaceutical.
Also for this aspect of the invention in which the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres, in preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen, and albumin.
The liposome may be a multilamellar vesicle or unilamellar vesicle.
Liposomes comprise phospholipids and/or sphingolipids and optionally lipids such as cholesterol and phosphatidic acid and antioxidants. Preferred phospholipids are soybean lecithin, egg lecithin, soybean phosphatidylcholine, egg phosphatidylcholine, synthetic phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidylethanolamine, alone or in mixtures. A preferred sphingolipid is sphingomyelin. Highly preferred liposomes comprise phosphatidylcholine, phosphatidylethanolamine, cholesterol and an antioxidant.
The microcapsule, microsphere, nanocapsule or nanosphere comprises polymers and optionally plasticizers and emulsifiers. The preferred polymers comprising these microcapsules, microspheres, nanocapsules or nanospheres are polyalkyl methacrylate such as polymethylmethacrylate, polyalkylcyanoacrylates such as polymethylcyanomethacrylate, polyesters such as polylactic acid and polylactic/glycolic acid copolymers, cellulose derivatives such as ethylcellulose and cellulose acetate and proteins such as albumin, gelatin, and hydrolyzed gelatin, and polysaccharides such as sodium alginate, pectin, chitosan, guar gum, and xanthan gum.
In alternate embodiments of the liquid composition of the invention the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In preferred such embodiments, the liquid composition comprises a mixture of the polymer, tannic acid or tannin, and a pharmaceutical entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres.
The minimal essential components of the liquid composition can be, therefore, a polymer, tannic acid or tannin, and the pharmaceutical entrapped in a liposome or microcapsule, microsphere, nanocapsule or nanosphere. However, it is to be understood that more than one polymer or type of polymer can be included. That is, more than one protein, more than one cellulosic polymer, and combinations of the two, are encompassed. It is further understood that more than one type of liposome or microcapsule, microsphere, nanocapsule or nanosphere or combination of any of them, are also encompassed.
Thus the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical entrapped 1 S in any of the liposomes or microcapsules, microspheres, nanocapsules or nanospheres, or combination of liposomes or microcapsules, microspheres, nanocapsules or nanospheres as disclosed herein.
Optional agents include plasticizers such as glycerol, polyethylene glycols, and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is a protein, and particularly hydrolyzed gelatin.
Emulsifiers may also be added optionally.
In highly preferred embodiments, also for this additional aspect of the invention in which the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres, the invention is directed to liquid compositions comprising a polymer and tannic acid or tannin and a pharmaceutical wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres and where the liquid composition dries to form an adhesive solid composition capable of controlled release of the pharmaceutical agent or forms a precipitate that is capable of being *rB
dried to form an adhesive solid composition capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, collagen, and albumin.
The liposomes may be a multilamellar vesicle or a unilamellar vesicle.
Liposomes comprise phospholipids and/or sphingolipids and optionally lipids such as cholesterol and phosphatidic acid and antioxidants. Preferred phospholipids are soybean lecithin, egg lecithin, soybean phosphatidylcholine, egg phosphatidylcholine, synthetic phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidylethanolamine, alone or in mixtures. A preferred sphingolipid is sphingomyelin. Highly preferred liposomes comprise phosphatidylcholine, phosphatidylethanolamine, cholesterol and an antioxidant.
The microcapsule, microsphere, nanocapsule or nanosphere comprises polymers and optionally plasticizers and emulsifiers. The preferred polymers comprising these or microcapsules, microspheres, nanocapsules or nanospheres are polyalkyl methacrylate such as polymethylmethacrylate, polyalkylcyanoacrylates such as polymethylcyanomethacrylate, polyesters such as polylactic acid and polylactic/glycolic acid copolymers, cellulose derivatives such as ethylcellulose and cellulose acetate and proteins such as albumin, gelatin, and hydrolyzed gelatin, and polysaccharides such as sodium alginate, pectin, chitosan, guar gum, and xanthan gum.
In alternate embodiments of the liquid composition of the invention the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
In such preferred embodiments, the liquid composition comprises a mixture of the polymer, tannic acid or tannin, and a pharmaceutical entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres.
The minimal essential components of the liquid composition can be, therefore, a polymer, tannic acid or tannin, and the pharmaceutical entrapped in a liposome or microcapsule, microsphere, nanocapsule or nanosphere. -However, it is to be understood that more than one polymer or type of polymer can be included. That is, more than one protein, more than one cellulosic polymer, and combinations of any of them, are encompassed. It is further understood that more than one type of liposome or microcapsule, microsphere, nanocapsule or nanosphere or combination of the two, are also encompassed.
Thus the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin, and the pharmaceutical entrapped in any of the liposomes or microcapsules, microspheres, nanocapsules or nanospheres, or combination of liposomes or microcapsules, microspheres, nanocapsules or nanospheres as disclosed herein.
Optional agents include plasticizers such as glycerol, polyethylene glycols, and citrate esters, glycerol being the particularly preferred plasticizer when the polymer is a protein, and particularly hydrolyzed gelatin.
Emulsifiers may also be added optionally.
The invention naturally encompasses solid compositions comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
Alternatively, the polymer is a cellulosic polymer. Preferred polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
Since the liquid composition can comprise a mixture of the polymer, tannic acid or tannin and the pharmaceutical, the solid composition accordingly comprises a mixture of a polymer, tannic acid or tannin, and a pharmaceutical.
WO 99!04764 PCT/US98115096 Thus, the pharmaceutical is dispersed or embedded in the dried matrix of the polymer-tannic acid/tannin.
The minimal essential components in the solid composition can include the polymer, tannic acid or tannin, and a pharmaceutical. It is understood, however, that the solid composition may contain more than one suitable polymer. Thus, the composition encompasses more than one protein, more than one cellulosic polymer, and combinations of the two.
Thus, the solid composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, as well as other appropriate proteins and cellulosic polymers, and tannic acid or tannin and the pharmaceutical.
When appropriate, the solid composition of this invention may be coated with a suitable pharmaceutical coating.
In preferred embodiments, the invention is directed to a solid adhesive composition comprising a polymer, tannic acid or tannin, and a pharmaceutical, where the solid composition is capable of controlled release of the pharmaceutical.
In preferred embodiments, the polymer is a protein. Preferred proteins include, but are not limited to, gelatin, hydrolyzed gelatin, albumin and collagen.
Alternatively, the polymer is a cellulosic polymer. Preferred cellulosic polymers include, but are not limited to, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
The solid adhesive composition comprises a mixture of a polymer, tannic acid or tannin and a pharmaceutical.
Thus, the pharmaceutical is dispersed or embedded in the dried adhesive matrix of the polymer-tannic acid/tannin.
The minimal essential components in the solid adhesive composition can be the polymer, tannic acid or tannin, and the pharmaceutical. It is understood, however, that the solid composition may contain more than one polymer. Thus, the composition encompasses more than one protein, more than one cellulosic polymer, and combinations of the two.
Accordingly, the composition can consist essentially of any of the proteins or cellulosic polymers disclosed herein, combinations thereof, as well as other appropriate polymers, and tannic acid or tannin, and a pharmaceutical.
The solid compositions described herein encompass biodegradable formulations.
Although the above description relates specifically to the release of pharmaceuticals, it is to be understood that other agents can be released from the solid compositions described herein. Examples of such agents include, but are not limited to, cosmetics, vitamins, minerals, flavorants, colorants, toxins such as pesticides, odorants, and the like.
For controlling the release of a pharmaceutical or other agent from the solid compositions disclosed herein, the agent can be entrapped in the polymeraannic acid matrix. The extent of such entrapment, and thereby the extent of sustained release, is controlled by the choice of polymer.
The solvents used to prepare the polymer-tannic complex can be useful as release-adjusting agents, since they can strongly affect the release rate, as shown in the examples herein.
An outer polymer matrix as shown in the examples herein, is a form of release-adjusting agent because it contributes to controlling the release of the drug. It can be formulated with or without its own release-adjusting agents, to retard release from the inner matrix by varying amounts.
Release of the pharmaceutical can also be controlled by the addition of pH-adjusting agents, release-adjusting agents, solubility-adjusting agents, and combinations thereof, to the solution or suspension of the polymer being added to the dried precipitate.
The invention is also directed to methods of making each of the compositions disclosed herein.
In its broadest embodiment, the polymer and tannic acid or tannin are mixed in a solvent, and the mixture is then dried to form the solid composition.
Alternatively, the polymer may be first dissolved in a solvent and the tannic acid or tannin separately dissolved in a solvent prior to mixing.
The polymer may or may not form a precipitate when mixed with the tannic acid or tannin. In embodiments in which the tannic acid or tannin forms a precipitate with the polymer, the composition is made as follows:
(1) the polymer is dissolved in a solvent, (2) tannic acid or tannin is added in a solvent, {3) a precipitate is allowed to form, (4) the precipitate is dried to form the solid composition.
A pharmaceuticals) can be added to the polymer solution or the tannic acid solution. When added to a polymer solution which will form a precipitate, the pharmaceutical is then mixed in the precipitate that is formed, so that when the precipitate is dried the pharmaceutical is embedded or dispersed in the solid composition formed from the precipitate.
In alternative embodiments, however, the solid composition can be formed as in steps 1-4 and then one or more pharmaceuticals can be added to this precipitate that is further processed for controlled release of the pharmaceuticals j from the dried precipitate. The drug can be added to the dried precipitate in solution and then subsequently dried or can be mixed in powdered form with the precipitate. This can then be pressed or otherwise formed together according to methods well known in the art.
Preferred solvents for the polymer include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
Preferred solvents for the tannic acid or tannin include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
When the polymer is a protein, preferred solvents include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
When the polymer is a cellulosic polymer, preferred solvents include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
When the polymer and tannic acid are dissolved in the same solvent, preferred solvents include, but are not limited to, water, ethanol, and mixtures of water and ethanol, isopropanol, mixtures of water and isopropanol, n-propanol, and mixtures of water and n-propanol.
In alternative embodiments, the dried precipitate disclosed above is ground into a powder, and the powder is then mixed with a further polymer in a solvent, and this mixture is then dried to form the final solid composition. This second polymer thus forms an outer matrix over the complex.
Preferred polymers for mixing with the polymer-tannic acid/tannin precipitate include any polymer that physically binds the powder together, allowing the powder to adhere to the tooth as a mass. The polymer needs to be flexible, and therefore, a plasticizer is essential. The polymer should be degradable and/or allow saliva to diffuse through it to allow for drug release from the powder.
The polymer should be either soluble or dispersible in a solvent in which the powder is insoluble, so that the powder will not re-dissolve when the polymer is added.
This second polymer can optionally be formulated with release-adjusting agents, pH-adjusting agents, emulsifiers, and solubility-adjusting agents.
The preferred second polymer is a polyacrylate polymer, and particularly a EudragitTM polymer.
Preferred polymers that can be used as a second polymer when the first polymer is a protein or a cellulosic polymer include, but are not limited to, EudragitTM L-100, EudragitTM L 30D-55, EudragitTM S-100, EudragitTM NE-100, EudragitTM NE-30, EudragitTM RL, EudragitTM RS, hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, pectin, calcium pectinate, *rB
WO 99/04764 ~ PCT/US98/15096 alginic acid, calcium alginate, cellulose acetate phthalate, carbopol, guar gum, gum tragacanth, gum acacia, other vegetable gums, and chitosan.
The second polymer serves as a matrix for the tannic-polymer-complex powder (precipitate). It binds the powder together for ease of application and control of dosage. That is, a premeasured amount of the pharmaceutical agents) can be applied in one single application, rather than in repeated applications (as in a varnish coated onto teeth, for example).
It further can help control the rate of releasing the drug by controlling or attenuating the ability of the saliva to interact with the precipitate. The degradation of the polymer and permeability with saliva allow for the release of the powder into the saliva and thereby for the release of the pharmaceutical.
In preferred embodiments, the composition is made as follows: ( 1 ) protein and a pharmaceutical are dissolved in a solvent comprising ethanol and water;
(2) tannic acid or tannin is added in a solvent comprising ethanol and water;
(3) a precipitate is allowed to form; (4) the precipitate is dried to form the solid composition.
In highly preferred embodiments, the first four steps above are performed but the following additional steps are then performed: (S) the dried precipitate is ground into a powder; (6) the powder is mixed with a EudragitTM polymer and a plasticizer in a solvent comprising ethanol and water or as a latex suspension in water; (7) the mixture is dried.
In highly-preferred embodiments of the invention, the protein is hydrolyzed gelatin and the second polymer is EudragitTM L-100.
Preferred pharmaceuticals include, but are not limited to, nicotine, nicotine salts, nicotine polymer complexes, lidocaine, piroxicam, flurbiprofen, dihydroergotamine mesylate, ergotamine tartarate, sumaptriptan succinate, isosorbide dinitrate, isosorbide mononitrate, nifedipine, ondansetron hydrochloride, and peptide drugs. Highly or significantly water-soluble pharmaceuticals are particularly suited for release from embodiments in which a protein-tannic acid/tannin precipitate has been formed. Embodiments including a second polymer are particularly suitable for releasing such pharmaceuticals.
In certain embodiments of the invention, the same or a-_ different pharmaceutical can be added in the second polymer solution and be released therefrom (when solidified).
The invention is also directed to the use of the solid compositions in the treatment of various conditions. The compositions can also be used as a powder or microcapsule in a capsule for oral delivery to the gastrointestinal tract, compressed into tablets alone or with typical excipients for oral delivery to the gastrointestinal tract, as a lozenge for local delivery to the oral cavity or for delivery to the gastrointestinal tract, a suppository for rectal delivery, a vaginal tablet or suppository, or as an ointment for topical use.
Accordingly, depending on the use of the compositions, the physical form of the composition can be adjusted. For example, the compositions may be used as a film, nanoparticle, microparticle or bead. The compositions could also be used as a powder or microcapsules in a capsule, compressed into tablets alone or with typical excipients, as a lozenge, suppository, vaginal tablet or suppository, or as an ointment. When appropriate, the composition of this invention may be coated with a suitable pharmaceutical coating.
In preferred embodiments, the invention is directed to a composition for sustained release of a pharmaceutical in the oral cavity. In a highly preferred form, the invention is in the form of a pharmaceutical oral patch that can be attached to the surface of a tooth, denture, or other hard dental structure.
The method provides for buccal absorption of an active agent resulting in rapid systemic delivery of desired amounts of agent for a desired period of time.
The method also provides for the delivery of an active agent confined to a tooth area and avoiding release elsewhere in the oral cavity.
The method also allows for localized treatment of affected sites in the oral cavity or throat area.
_27_ The invention also provides a patient with the compositions described herein by adhesively adhering the solid, sustained-release composition to the hard surface of the patient's mouth, for example, teeth or dentures As a pharmaceutical oral patch, the solid composition can be modified into any shape and size, depending on the purposes of drug release. Thus, if large amounts of a drug are to be released, in addition to increasing the concentration of drug, in the sustained-release composition, the solid form can be larger in size and/or greater in thickness.
The important consideration for shape and size is that the patch does not confer unusual sensation to the patient when applied, and can effectively release the desired pharmaceutically active agent at the desired levels and for the desired duration of time. For example, for the rapid release of a small amount of drug, a thin layer, in which the drug is dispersed, may be required.
The following considerations are important in choosing the site of application: (1) the salivary flow around the site; (2) the accessibility for application; (3) the comfort of the patient.
Patch components are suitable to remain in the oral cavity for prolonged periods of time. In a preferred embodiment, the patch remains in the oral cavity between 6 to 8 hours. However, other embodiments can last for various desired periods of time.
The invention is also directed to a method for making the sustained-release compositions so that the rate of release can be adjusted in the final, solid form.
The invention is also directed to methods for using the compositions of the present invention to release appropriate pharmaceutical agents in the oral cavity.
Potentially, any pharmaceutically active agent can be released, although, as mentioned, the preferred agents are those that are soluble or very soluble in water.
In addition, potentially any condition can be treated by means of the release of a pharmaceutical from the patch. These are described in more detail below.
Preferred sites of application include but are not limited to the upper teeth.
WO 99!04764 PCT/US98/15096 The sites of action for the pharmaceutically active agents include the oral mucosa of the mouth, throat, and esophagus per se, systemic delivery via the oral mucosa, or localized delivery to one or more teeth.
The amount of active agent included in the final, controlled release product S can be determined by one skilled in the art without undue experimentation, and is generally from about 0.1% to about 35% by weight of the final product. The particular amount of the active agent included will, of course, depend upon the particular agent and its intended use.
The present invention can include other locally active agents, such as flavorants and sweeteners. The flavoring agents may be natural or synthetic.
The flavoring agent is a common flavorant including wintergreen, peppermint, spearmint, menthol, fruit flavors, vanilla, cinnamon, various spices, or others known in the art. Generally any flavoring or food additive, such as those described in Chemical Used in Food Processing, Pub. No. 1274, National Academy of Sciences, pages 63-258, can be used. The amount of flavoring employed is normally a matter of preference subject to such factors as flavor type, individual flavor, and strength desired. Generally, the final product includes from about 0.1 % to about 5% weight flavorant.
Sweeteners useful in the present invention include sucrose and aspartame.
In general, sweeteners (when present) are included in an amount from about 0.001 % to about 5.0% by weight of the final product.
Effective amounts of coloring agents (e.g., titanium dioxide, F.D. & C., and D. & C. dyes; see the Kirk-Othmer Encyclopedia of Chemical Technology, vol. 5, pp. 857-884); softeners, stabilizers, binders, odor-controlling agents, and preservatives can also be contained in the patch, as long as they do not impair adhesiveness or impede pharmacological effects.
The term "therapeutically effective amount" is intended to mean the amount of pharmaceutically active agent sufficient to produce the desired effect when released from the dental patch described herein. These amounts are known in the art or may be determined by methods known in the art. The amounts depend upon the agents chosen and whether the site of action is the tooth per se, the oral mucosa (and the region of the oral mucosa), or systemic.
The upper limit on the amount of drug in the composition is determined by the properties of the polymeric matrix and the chemical interaction of the drug with the polymeric matrix.
The amount of active agent in the composition necessary to provide the desired amounts and concentration in the oral cavity can be determined by known methods. Thus, the concentration and the quantity of the agent per unit area of the patch (i.e., per square or cubic millimeter) can be varied independently in order to achieve a desired effect. Higher concentrations of agent contained in a dosage form of decreased thickness will result in an agent with fast onset and short duration. High concentrations of an agent contained in a dosage form of increased thickness (higher milligrams of agent per square or cubic millimeter) will result in potent effect with fast onset and long duration. Low concentrations of the agent in a dosage form of decreased thickness will result in mild effect with longer onset and short duration. Low concentrations of the agent contained in a dosage form of increased thickness will have mild effect with longer onset and longer duration.
As shown in the above explanation, the ability to coat thin or thick, enables the practitioner of the invention to vary the dosage of the system as needed for particular anatomical sites of interest and according to the specific drug.
The term "onset" is intended to mean the time needed to reach the desired concentration level of the pharmaceutical agent. It is used according to its normal and art-recognized meaning.
The term "duration" as used herein, means the period of time during which the desired concentration of pharmaceutical agent is delivered. This term is used according to its normal and art-recognized meaning.
The term "adhesive" as used herein, means an adhesive which attaches, and preferably strongly attaches, the release layer to teeth or other hard structures in the mouth such as dentures. To qualify as an adhesive, the substance must be capable of maintaining adhesion in the moist or wet environments of the oral cavity. It can also be "self adhesive" in that it attaches to the site of interest without the need to reinforce its attachment by way of another adhesive. Thus, the term "adhesive" is used according to its normal and art-recognized meaning.
Adhesion can only be quantified with reference to a specific type of test or S usage. It is not in itself a basic physical property, such as the surface free energy or the film thickness, whose measurement can be accomplished by a variety of methods. "Adhesion performance" must therefore be defined and measured in the context of the application of interest. Whether a given adhesive is effective for the oral cavity can be determined by a peel test in artificial saliva.
1 U The strength of adherence can be measured by standard tests for measuring the force, for example in dynes per square centimeter, as disclosed in U.S.
Patent No. 4,615,697.
The term "subject" or "patient" is intended to include all mammals, preferably humans.
15 The term "patch", as used herein, is intended to mean a three-dimensional solid composition that can be adhered to teeth, or other hard structures in the mouth, such as dentures, which can contain a pharmaceutically active agent, and which can release the pharmaceutically active agent in effective amounts, for a desired period of time, from its site of attachment within the oral cavity.
20 By "pharmaceutically active agent" is intended any chemical or biochemical that can be released from the dental patch to prevent, cure, or ameliorate an undesirable physiological condition (see below). The term "drug" is used interchangeably herein. These terms are used according to their normal and art-recognized meanings.
25 Although any agent can be used, depending on the purpose of therapy, the following are exemplary:
1. anti-inflammatory, analgesic agents: content 0.1-5%
2. steroidal anti-inflammatory agents: content 0.002-0.5%
3. antihistamines:0.l-2%
30 4. local anesthetics: 0.05-2%
5. bacteriocides and disinfectants: 0.01-10%
6. vasoconstrictors: 0.01-1
7. hemostatics:0.05-1%
8. chemotherapeutics:0.05-1%
9. antibiotics:0.001-10%
10. cosmetics
11. tooth desensitizing agents: 0.1-10%
12. antifungals:0.1-10%
13. vasodilators:0.1-10%
14. antihypertensives:0.1-10%
15. antiemetics:0.1-10%
16. antimigraine:0.1-10%
17. antiarrhythmics:0.1-10%
18. antiasthmatics:0.1-10%
19. antidepressants:0.1-10%
20. vaccines:0.1-1%
21. peptides:0.1-1%
22. hormones:0.1-1%
23. anti-proton pumps or H receptor blockers: 0.1-10%
24. smoking cessation aids: 1-S%
Examples of anti-inflammatory, analgesic agents include acetaminophen, methyl saiicylate, monoglycol salicylate, aspirin, mefenamic acid, flufenamic acid, indomethacin, diclofenac, alclofenac, diclofenac sodium, ibuprofen, flurbiprofen, fentizac, bufexamac, piroxicam, phenylbutazone, oxyphenbutazone, clofezone, pentazocine, mepirizole, and tiaramide hydrochloride.
Examples of steroidal anti-inflammatory agents include hydrocortisone, predonisolone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, hydrocortisone acetate, predonisolone acetate, methylpredonisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, flourometholone, beclomethasone dipropionate, and budesonide.
Examples of antihistamines include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine hydrochloride, chlorpheniramine maleate, isothipendyl hydrochloride, tripelennamine hydrochloride, promethazine hydrochloride, and methdilazine hydrochloride.
Examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino) ethyl ester hydrochloride, procaine hydrochloride, tetracaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine hydrochloride, mepivacaine, cocaine hydrochloride, and piperocaine hydrochloride.
Examples of bacteriocides and disinfectants include thimerosol, phenol, thymol, benzalkonium chloride, benzethonium chloride, chlorhexidine, providone iodide, cetylpyridinium chloride, eugenol, and trimethylammonium bromide.
Examples of vasoconstrictors include naphazoline nitrate, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride, and tramazoline hydrochloride.
Examples of hemostatics include thrombin, phytonadione, protamine sulfate, aminocaproic acid, tranexamic acid, carbazochrome, carbaxochrome sodium sulfonate, rutin, and hesperidin.
Examples of chemotherapeutic drugs include vinblastine, cis-platin, 5-fluorouracil (SFU), methotrexate (MTX), 6 mercaptopurine (6MP), 1-~3-D-arabinofuranosylcytosine (ara-C), mechlorethamine, chlorambucil, melphalan oxazaphosphorines, carboplatin, JM40, spiroplatin, tetraplatin, JM216, and taxol.
Examples of antibiotics include penicillin, meticillin, oxacillin, cefalotin, cefaloridin, erythromycin, lincomycin, tetracycline, chlortetracycline, oxytetracycline, metacycline, chloramphenicol, kanamycin, streptomycin, gentamicin, bacitracin, and cycloserine.
Examples of antifungal drugs include amphotericin, clotrimazole, econazole nitrate, fluconazole, grisofulvin, itraconazole, ketoconazole, miconazole, nystatin, terbinafine hydrochloride, undecenoic acid, and zinc undeconoate.
WO 99/04764 ~ PCT/US98/15096 Examples of vasodilator drugs include buflomedil hydrochloride, bucheneine hydrochloride, naftidrofury oxalate, oxpentifylline, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate and pentaerythritol tetranitxate.
Examples of antihypertensive drugs include amlodipine, benazepril hydrochloride, captopril, clonidine hydrochloride, diazoxide, diltiazem, hydrochloride, enalapril maleate, enalaprilat, felodipine, isradipine, nicardipine hydrochloride, nifedipine, atenolol, metoprolol tartarate, oxpenolol hydrochloride, propranolol hydrochloride and verapamil hydrochloride.
Examples of antiarrhythmic drugs include quinidine, quinidine salts, procainamide hydrochloride, lidocaine, and mexiletine hydrochloride.
Examples of antiemetic drugs include metoclopramide hydrochloride, nabilone, and ondansetron hydrochloride.
Examples of proton pump inhibitors or H receptor Mockers include omeprazole, ranitidine and cimetidine.
Examples of antimigraine drugs include dihydroergotamine mesylate, ergotamine tartarate, sumatriptan succinate and other triptan drugs.
Examples of peptide or protein drugs include insulin, buserelin acetate, goserlin acetate, leuprorelin acetate, calcitonin, cyclosporin, gonadorelin, somastatin, vasopressin, oxytocin, interferon, and human growth hormone.
Examples of antidepressant drugs include fluoxetine hydrochloride, imipramine, maprotiline hydrochloride, and phenelzine sulfate.
Examples of antiasthmatics include salbutamol and terbutaline sulfate.
Examples of smoking cessation aids include nicotine, nicotine salts, nicotine polymer complexes, and cotinine.
Examples of cosmetics include breath fresheners and tooth whiteners.
When release of the agent is localized to the teeth, preferred agents include tooth-whitening agents, such as carbamide peroxide, and tooth-desensitizing agents, such as potassium nitrate and strontium chloride.
The conditions amenable to treatment with the patch described herein include, but are not limited to oral infections, lesions, low or high blood pressure, *rB
WO 99/04764 ~ PCT/US98/15096 Helicobacter infections, pain, cough, migraine, vomiting, nausea, inflammation, sleep apnea, snoring, gerd and reflux disease. Preferred conditions include yeast infections, periodontal diseases, snoring, oral ulcers or other lesions.
The invention will now be illustrated in greater detail with reference to the following examples, but it should be understood that these are not intended to limit the present invention.
Examples Example 1 Prolonged Sustained Release of Highly Soluble Drugs Materials and Methods Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Nicotine was purchased from The Nicobrand Company.
Pilocarpine was purchased from Laob.
Preparation of Formulations Hydrolyzed gelatin and the drug (nicotine or pilocarpine) were dissolved in a mixture of ethanol and water (or water atone). A solution of tannic acid in water and ethanol (or water alone) was added. The precipitate that formed was air-dried to constant weight and ground to a powder.
In Vitro Release Experiments The powder (0.5 gm) was inserted into dialysis bags which werestirred in 100 ml phosphate buffer (O.O1M, pH 7.4) at room temperature. Samples of 0.5 ml were taken for analysis.
Results Formulations of nicotine and pilocarpine, both highly soluble drugs, were prepared. These formulations, used to illustrate the controlled release of highly soluble drugs, are given in Tables 1-2.
Table 1: Liquid Formulation 245-49 (nicotine) Ingredient Weight Hydrolyzed gelatin 10 1N HCl 6 Nicotine I
Ethanol 40 Water 33 Tannic acid 10 Table 2: Liquid Formulation 245-43C (pilocarpine) Ingredient Weight Pilocarpine 0.3 Hydrolyzed gelatin 9 Tannic acid 9 Water 81.7 The in vitro release of the active ingredients from the powders obtained from these formulations was tested. The results are summarized in Tables 3-4.
Table 3: In ease of NicotineFormulation Vitro Rel from 245-49 Time (hr) % Cum Rel % Cum Rel 0.25 I .99 3.50 0.5 3.19 5.45 1 5.18 7.39 2 8.76 10.50 3 12.35 16.34 4 17.93 23.35 5 21.91 26.85 6 25.10 30.74 7 27.09 35.80 Table 4: In Vitro Release of Pilocarpine from Formulation Time (hr) % Cum Rel 0.25 2.77 0.5 5.03 1 7.28 2 14.22 3 19.77 4 25.32 5 31.56 6 37.46 7 42.66 8 47.86 WO 99/04764 ~ PCT/US98115096 The results show that one can control the release of highly soluble drugs with these formulations. The release can take place over many hours with less than half the drug having been released in eight hours.
Example 2 Control Over the Rate of Drug Release in Prolonged Controlled Release of a Highly Soluble Drug: I
Materials and Methods Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Sodium salicylate was purchased from Merck.
Preparation of Formulation The powder of gelatin-tannic acid was formulated with the highly soluble drug sodium salicylate and prepared using two different ratios of ethanol and water. in formulation 245-66A the weight proportion of the solvent was 3:1 {ethanol : water) and in formulation 245-68A it was 1:1.
Results The formulations used are described in Tables 5-6.
Table 5: Liquid Formulation 245-66A
Ingredient Weight Hydrolyzed gelatin 10 Sodium Salicylate I
Water 19 Ethanol 60 Tannic acid l0 Table 6: Liquid Formulation Ingredient Weight Hydrolyzed gelatin 10 Sodium Salicylate 1 Water 39.5 Tannic acid 10 Ethanol 39.5 1 S In vitro release studies were carried out on the powders obtained from these formulations as in Example 1.
The results of the in vitro release studies are summarized in Tables 7 and 8.
WO 99!04764 PCT/US98/15096 Table 7: In Vitro Release of Sodium Salicyiate from Formulation Time (hr) % Cumulative % Cumulative Release ._ Release 0.25 I 5 24 0.5 21 34 Table 8: In Vitro Release of Sodium Salicylate from Formulation Time (hr) % Cumulative % Cumulative Release Reiease 0.25 9 14 0.5 15 20 One can see that a high proportion of water in the solvent mixture decreases the release rate of the active ingredient while a higher ethanol content increases the release rate. In both cases one has prolonged release of the highly soluble substance, sodium salicylate, from the matrix.
Example 3 Control Over the Rate of Drug Release in Prolonged Controlled Release of a Highly Soluble Drug: ll Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulation The powder of gelatin-tannic acid was formulated with the highly soluble drug nicotine and prepared using two different ratios of ethanol and water. In formulation 245-70 the weight proportion of the solvent was 3:1 (ethanol:water) and in formulation 245-49 it was 1:1.
Results The formulations are given in Tables 9 and 10.
WO 99/04764 ~ PCT/US98/15096 Table 9: Liquid Formulation Ingredient Weight Hydrolyzed gelatin10 1N HCl 5 Nicotine 1 Water 17 Ethanol 57 Tannic acid 10 Table 10: Liquid Formulation Ingredient Weight Hydrolyzed gelatin10 Nicotine 1 Water 34 Ethanol 39 Tannic acid 10 In vitro release studies were carried out on the powders obtained from these formulations as in Example 1.
The release pattern of nicotine from formulations 245-70 and 241-49 is illustrated in Tables 11 and 12.
Table 11: Release of Nicotine mulation 245-70 from for Time (hr) % Cumulative % Cumulative Release Release 0.25 15 12 0.5 20 17 Table 12: ReleaseNicotine from ation 245-49 of formul Time (hr) % Cumulative % Cumulative Release Release 0.25 4.5 4 0.5 6 S
As it was shown for sodium salicylate, the effect of the solvent mixture was achieved with nicotine also. Increased amounts of water in the solvent mixture during the preparation of the formulation results in slower release.
WO 99/04764 ~ PCTIi1S98/15096 Example 4 Prolonged Sustained Release of Nicotine from a Pharmaceutical Oral Patch Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit L-100, Eudragit 30D-SS and triethyl citrate NF were purchased from Rhom Pharma.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulations The patch was formed by mixing the powder formed from Formulation 245-70 (Table 9) with an ethanolic solution of Eudragit L-100 and a plasticizer.
The mixture was transferred to plastic molds and dried to form an adhesive pharmaceutical oral patch.
In Vitro Release The dry patches (300 mg) were stirred in 100 ml buffer (phosphate, 0.01 M, pH 7.4) at room temperature. Samples of the solution (0.5 ml) were analyzed.
Results In vitro release experiments were carried out. The results are summarized in Table 13.
Table 13: In Vitro Release of Nicotine from a Pharmaceutical Oral Patch Time (hr) % Cumulative % Cumulative Release _ Release 0.25 2 3.5 0.5 3.2 5.5 1 5.2 7.4 2 8.8 10.5 3 12.4 16.3 4 17.9 23.4 5 21.9 26.9 6 25.1 30.7 7 27.1 35.8 Example S
Prolonged Sustained Release of Pilocarpine from a Pharmaceutical Oral Patcl:
Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit L-100, Eudragit 30D-SS and triethyl citrate NF were purchased from Rhom Pharma.
Pilocarpine was purchased from Laob.
Preparation of Formulations The patch was formed by mixing the powder formed from Formulation 245-43C (Table 2) with a water suspension of Eudragit L 30D-55.
The mixture was transferred to plastic molds and dried to form a S pharmaceutical oral patch.
In Vitro Release The dry patches (300 mg) were stirred in 100 ml buffer (phosphate, 0.01 M, pH 7.4) at room temperature. Samples (0.5 ml) of the solution were analyzed.
Results In vitro release experiments were carried out. The results are summarized in Table 14.
Table 14: In Vitro Release of Pilocarpine from a Pharmaceutical Oral Patch ~ Time (hr) % Cumulative % Cumulative Release Release 0.25 7.9 4.3 0.5 11.6 6.2 1 16.1 8.5 3 27 15.1 4 31.1 17.8 5 32.6 21.6 The results show that one can control the release of soluble drugs from a pharmaceutical oral patch for several hours.
Example 6 In Vitro Release of Nicotine from an _ Adhesive Pharmaceutical Oral Patch Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit L-100 and Triethyl Citrate NF were purchased from Rhom Pharma.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulations The patch was formed by mixing the powder formed from liquid Formulation 158-72 (Table 15), with an ethanolic solution of Eudragit L-100 and a plasticizer.
The mixture was transferred to plastic molds and dried to form an adhesive pharmaceutical oral patch.
Table 15: Liquid Formulation 158-72 Ingredient Weight Hydrolyzed gelatin28 37% HCI 0.5 Nicotine t Water 47.5 Ethanol 3 Tannic acid 20 In Vivo Release Experiment The pharmaceutical oral patch (190 mg), containing 2 mg nicotine, was attached to the buccal side of an upper molar tooth by means of self adhesion.
Saliva samples were expectorated at given time intervals and tested for nicotine content.
Results One volunteer wore the pharmaceutical oral patch for a period of four hours. The patch conformed to the contour of the tooth and was comfortable to wear. Saliva samples were collected and analyzed by chromatography. The results are listed in Table 16.
Table 16: In Vivo Release of Nicotine from a Pharmaceutical Oral Patch Time (min) Concentration (ppm) 0 0.3 15 13.4 30 25.1 60 23.8 90 51.6 120 20.1 180 26.3 240 18.1 The results indicate that clinically significant concentrations of nicotine as an example of soluble drug, can be maintained in the oral cavity for several hours.
The pharmaceutical oral patch self adhered to the tooth for the entire period of the experiment.
WO 99/04764 - PCT/C1S98l15096 Example 7 In Vivo Release of Nicotine from a Second Adhesive Pharmaceutical Oral Patch Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit 30D-55 and Triethyl Citrate NF were purchased from Rhom Pharma.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulations The patch was formed by mixing the powder formed from liquid Formulation 41 B001 SL (Table 17) with an aqueous suspension of Eudragit L
30D-55 and a plasticizer.
The mixture was transferred to plastic molds and dried to form an adhesive pharmaceutical oral patch.
Table 17: Liquid Formulation 41BOO1SL
Ingredient Weight Hydrolyzed gelatin27.5 37% HCl I
Nicotine I .6 Water 46.5 Ethanol 3.2 Tannic acid 20.1 *rB
WO 99/04764 ~ PCT/US98/15096 In Vivo Release Experiment The pharmaceutical oral patch (115 mg), containing 2 mg nicotine, was attached to the buccal side of an upper molar tooth by means of self adhesion.
Saliva samples were expectorated at given time intervals and tested for nicotine content.
Results One volunteer wore the pharmaceutical oral patch for a period of four hours. The patch conformed to the contour of the tooth and was comfortable to wear. Saliva samples were collected and analyzed by chromatography. The results are listed in Table 18.
Table 18: In Vivo Release of Nicotine from a Pharmaceutical Oral Patch Time (min) Concentration (ppm) 0 0.3 30 2.7 60 5.6 120 11.3 180 28.6 240 0.7 The results indicate that clinically significant concentrations of nicotine can be maintained in the oral cavity for several hours. The pharmaceutical oral patch self adhered to the tooth for the entire period of the experiment.
Example 8 Release of Liposome Encapsulated Nicotine from Pharmaceutical Oral Patches Nicotine was entrapped in liposomes of both the multilamellar vesicle (MLV) and small unilamellar vesicle (SUV) type. The formulations used for the formation of the Iiposomes are given in Table 19.
Table 19: Ingredients of MLV and SUV Liposomes:
Type Materials weight(g)mole%
NlCOtine Egg Phosphatidylcholine1 60.9 (PC) 99% Synthetic Liposomes 0.1 6.6 MLV
Phosphatidylethanolamine (PE) 99% 0 32 Cholestero195% . .
NiCOtine Soybean Phosphatidyicholine1,2 62.8 (PC) Liposomes Synthetic 0.12 6.8 SUV
Phosphatidylethanolamine (PE) 99% 0 4 Cholestero195% . .
The phospholipids and lipids were dissolved in 25 ml chloroform:methanol (2:1 ) in a round bottom flask of 100-1000 ml. The lipid solution was dried for 2 hours to form a lipid film onto the sides of the flask, using a rotary evaporator apparatus. The lipids were hydrated by addition of 10-20 ml H20 or PBS
(phosphate buffered saline) solution (0.01 M, pH 7.4), followed by vortexing and shaking in a 37°C water bath, for 2-4 hours to form MLV liposomes. The liposomes were characterized by standard chemical and electron microscope techniques.
MLV Nicotine Liposomes:
Nicotine (0.2 ml), a volatile and water soluble drug, was dissolved in an aqueous medium and added to the lipid film at the hydration step.
SUV Nicotine Liposomes:
WO 99/04764 ~ PCT/US98/15096 Nicotine (0.2 ml), in an aqueous medium was added to placebo liposomes (MLV) followed by 1 hour sonication to form nicotine liposomes of type SUV.
The percent entrapment of the nicotine was determined for each type of liposome and is shown in Table 20.
Table 20: Efficiency of Nicotine Encapsulation in Liposomes:
Type of liposomes % of encapsulation One can see that nicotine encapsulation in the liposomes was as expected for a water soluble drug. More drug was encapsulated in the SUV than in the MLV due to the higher percent internal aqueous volume in this form of liposome.
The liposomes were stored at 4°C (closed tightly).
Pharmaceutical oral patches were made using nicotine trapped in MLV
liposomes with and without an outer polymer matrix. The other ingredients of the patches are given in Table 21.
Table 21: Non Active Ingredients of Patches:
Materials Batch# Batch# Batch# Batch# Batch#
~'gt w'gt ~'gt ~'gt H'gt (g) fig) fig) (g) (g) H20 3.3 3.3 3.1 33 33 BycoE 2.6 2.6 3.1 26 26 H20 1.1 1.1 1.3 11 11 Ethanol 0.3 0.3 - 3 3 Tannic Acid 1.9 1.9 1.7 19 19 MatrIX(Elldr.L-30D+Glycerin)'~' - -lVlatCIX (Eudr.L-100+Ethanol)- 'f' - + +
Patches of Batches# 285-23A, 285-23B:
2g of MLV liposomes containing entrapped nicotine were suspended in water. BycoE~'~"'' was added and finally a solution of tannic acid in ethanol-water was added. The precipitate was dried at 50 ° C, ground to a powder and mixed with a polymer matrix based on EudragitT"" (approx. 1:1 ). Polypropylene molds were filled with the mixture (190mg/well) and dried at 35°C. These patches contain ~2 mg nicotine each and are formed with an outer polymer matrix.
Patches of Batch# 285-28:
Solution of tannic acid in water was added dropwise into solution of Byco 1 O ET"'. 0.45g of the tannic acid-Byco preparation were mixed with 0.63g of MLV
liposomes containing entrapped nicotine. Polypropylene molds were filled with the mixture (280mg/well) and dried at 35 °C in the oven. These patches contain ~2 mg nicotine each and are formed without an outer polymer matrix.
Patches without liposomes # 49A004 and 158-64:
Nicotine neutralized with HCl was dissolved in water. Byco ETM was added and finally a solution of tannic acid in ethanol-water was added. The precipitate was dried at 50°C, ground to a powder and mixed with a polymer matrix based on EudragitT"" (approx. 1:1 ). Polypropylene molds were filled with the mixture (190mg/well) and dried at 35 °C. These patches contain ~2 mg nicotine each and are formed with an outer polymer matrix.
Release Assays:
In vitro: Patches containing liposomes were introduced into dialysis tubes with a molecular weight cutoff of 50,000 and stirred in bulk solutions of 50-ml phosphate buffered saline (PBS) (O.O1M, pH 7.4). 0.2m1 samples were collected at times 0-7h. The nicotine was determined by a validated HPLC
method.
In vivo: The pharmaceutical oral patch was attached to an upper back tooth. Saliva samples were collected at times 0-180 min. The nicotine was determined by a validated HPLC method.
Results in Vitro:
The average results of release of nicotine from the in vitro pharmaceutical oral patches are summarized in Figure 1.
The release of drug from liposomal patches #285-28 (V) was slower than from the non liposomal nicotine patches #49A004 (VI-VIII). The release of nicotine from both of these types of patches was characterized by a single rate constant. In contrast, the release profile of nicotine from liposomal patches #285-23A (I and II) and #285-23B (III and IV), was characterized by a two phase release of the drug and was also slower than the non-liposomal formulation.
Results in Vivo:
The release experiment of nicotine in vivo was performed, using patch #285-28 containing centrifuged nicotine liposomes type MLV and compared to non-liposomal nicotine patch #158-64. The results are shown in Figure 2.
One sees that salivary concentrations of nicotine were higher for the formulation without liposomes. The profiles of release were similar.
Example 9 Release of Liposome Encapsulated Flurbiprofen from Pharmaceutical Oral Patches Flurbiprofen was entrapped in multilamellar vesicle type liposomes as follows:
Soybean phosphatidylcholine ( 14 gm) was dissolved in 100 ml ethanol in a 1000 ml round bottom flask along with 2.3 gm flurbiprofen. The lipid solution was dried for 1.5 hours to form a lipid film with flurbiprofen dispersed therein.
onto the sides of the flask, using a rotary evaporator apparatus. The lipids were hydrated by addition of 140 ml HzO, followed by rotation for 2 hours-and slow stirring for 1 hour to form MLV liposomes. The liposomes were characterized by standard chemical and electron microscope techniques. The non-encapsulated flurbiprofen was removed by dialysis. The liposomes were obtained by centrifugation at 10°C for 1 hour at 17500 rpm.
Patches of Batch# 285- 62:
Tannic acid (1.7 gm) in 1.3 gm water was added dropwise to a solution of 3.1 gm hydrolyzed gelatin (BycoETM) in water. The tannic acid - hydrolyzed gelatin preparation was mixed with 9.6 gm of MLV liposomes containing entrapped flurbiprofen. Polypropylene molds were filled with the mixture (200 mg/well) and the patches were dried in an oven at 30°C.
Release Assays:
In vitro: Patches containing liposomes were stirred in bulk solutions of 100 ml PBS (0.01 M, pH 7.4). 0.2m1 samples were collected at times 0-7h. The flurbiprofen was determined by a validated HPLC method.
Results in Vitro:
The average results of the in vitro release of flurbiprofen from the pharmaceutical oral patches are summarized in Figure 3 and Table 22. One can see clear sustained release of the flurbiprofen from the patches.
Table 22: Cumulative Release of Flurbiprofen Time % cumulative release 15 7.53 30 10.94 60 ~ 15.37 -SS-120 21.12 180 27.19 240 30.81 300 33.66 360 37.44
Examples of anti-inflammatory, analgesic agents include acetaminophen, methyl saiicylate, monoglycol salicylate, aspirin, mefenamic acid, flufenamic acid, indomethacin, diclofenac, alclofenac, diclofenac sodium, ibuprofen, flurbiprofen, fentizac, bufexamac, piroxicam, phenylbutazone, oxyphenbutazone, clofezone, pentazocine, mepirizole, and tiaramide hydrochloride.
Examples of steroidal anti-inflammatory agents include hydrocortisone, predonisolone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, hydrocortisone acetate, predonisolone acetate, methylpredonisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, flourometholone, beclomethasone dipropionate, and budesonide.
Examples of antihistamines include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine hydrochloride, chlorpheniramine maleate, isothipendyl hydrochloride, tripelennamine hydrochloride, promethazine hydrochloride, and methdilazine hydrochloride.
Examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino) ethyl ester hydrochloride, procaine hydrochloride, tetracaine hydrochloride, chloroprocaine hydrochloride, oxyprocaine hydrochloride, mepivacaine, cocaine hydrochloride, and piperocaine hydrochloride.
Examples of bacteriocides and disinfectants include thimerosol, phenol, thymol, benzalkonium chloride, benzethonium chloride, chlorhexidine, providone iodide, cetylpyridinium chloride, eugenol, and trimethylammonium bromide.
Examples of vasoconstrictors include naphazoline nitrate, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride, and tramazoline hydrochloride.
Examples of hemostatics include thrombin, phytonadione, protamine sulfate, aminocaproic acid, tranexamic acid, carbazochrome, carbaxochrome sodium sulfonate, rutin, and hesperidin.
Examples of chemotherapeutic drugs include vinblastine, cis-platin, 5-fluorouracil (SFU), methotrexate (MTX), 6 mercaptopurine (6MP), 1-~3-D-arabinofuranosylcytosine (ara-C), mechlorethamine, chlorambucil, melphalan oxazaphosphorines, carboplatin, JM40, spiroplatin, tetraplatin, JM216, and taxol.
Examples of antibiotics include penicillin, meticillin, oxacillin, cefalotin, cefaloridin, erythromycin, lincomycin, tetracycline, chlortetracycline, oxytetracycline, metacycline, chloramphenicol, kanamycin, streptomycin, gentamicin, bacitracin, and cycloserine.
Examples of antifungal drugs include amphotericin, clotrimazole, econazole nitrate, fluconazole, grisofulvin, itraconazole, ketoconazole, miconazole, nystatin, terbinafine hydrochloride, undecenoic acid, and zinc undeconoate.
WO 99/04764 ~ PCT/US98/15096 Examples of vasodilator drugs include buflomedil hydrochloride, bucheneine hydrochloride, naftidrofury oxalate, oxpentifylline, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate and pentaerythritol tetranitxate.
Examples of antihypertensive drugs include amlodipine, benazepril hydrochloride, captopril, clonidine hydrochloride, diazoxide, diltiazem, hydrochloride, enalapril maleate, enalaprilat, felodipine, isradipine, nicardipine hydrochloride, nifedipine, atenolol, metoprolol tartarate, oxpenolol hydrochloride, propranolol hydrochloride and verapamil hydrochloride.
Examples of antiarrhythmic drugs include quinidine, quinidine salts, procainamide hydrochloride, lidocaine, and mexiletine hydrochloride.
Examples of antiemetic drugs include metoclopramide hydrochloride, nabilone, and ondansetron hydrochloride.
Examples of proton pump inhibitors or H receptor Mockers include omeprazole, ranitidine and cimetidine.
Examples of antimigraine drugs include dihydroergotamine mesylate, ergotamine tartarate, sumatriptan succinate and other triptan drugs.
Examples of peptide or protein drugs include insulin, buserelin acetate, goserlin acetate, leuprorelin acetate, calcitonin, cyclosporin, gonadorelin, somastatin, vasopressin, oxytocin, interferon, and human growth hormone.
Examples of antidepressant drugs include fluoxetine hydrochloride, imipramine, maprotiline hydrochloride, and phenelzine sulfate.
Examples of antiasthmatics include salbutamol and terbutaline sulfate.
Examples of smoking cessation aids include nicotine, nicotine salts, nicotine polymer complexes, and cotinine.
Examples of cosmetics include breath fresheners and tooth whiteners.
When release of the agent is localized to the teeth, preferred agents include tooth-whitening agents, such as carbamide peroxide, and tooth-desensitizing agents, such as potassium nitrate and strontium chloride.
The conditions amenable to treatment with the patch described herein include, but are not limited to oral infections, lesions, low or high blood pressure, *rB
WO 99/04764 ~ PCT/US98/15096 Helicobacter infections, pain, cough, migraine, vomiting, nausea, inflammation, sleep apnea, snoring, gerd and reflux disease. Preferred conditions include yeast infections, periodontal diseases, snoring, oral ulcers or other lesions.
The invention will now be illustrated in greater detail with reference to the following examples, but it should be understood that these are not intended to limit the present invention.
Examples Example 1 Prolonged Sustained Release of Highly Soluble Drugs Materials and Methods Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Nicotine was purchased from The Nicobrand Company.
Pilocarpine was purchased from Laob.
Preparation of Formulations Hydrolyzed gelatin and the drug (nicotine or pilocarpine) were dissolved in a mixture of ethanol and water (or water atone). A solution of tannic acid in water and ethanol (or water alone) was added. The precipitate that formed was air-dried to constant weight and ground to a powder.
In Vitro Release Experiments The powder (0.5 gm) was inserted into dialysis bags which werestirred in 100 ml phosphate buffer (O.O1M, pH 7.4) at room temperature. Samples of 0.5 ml were taken for analysis.
Results Formulations of nicotine and pilocarpine, both highly soluble drugs, were prepared. These formulations, used to illustrate the controlled release of highly soluble drugs, are given in Tables 1-2.
Table 1: Liquid Formulation 245-49 (nicotine) Ingredient Weight Hydrolyzed gelatin 10 1N HCl 6 Nicotine I
Ethanol 40 Water 33 Tannic acid 10 Table 2: Liquid Formulation 245-43C (pilocarpine) Ingredient Weight Pilocarpine 0.3 Hydrolyzed gelatin 9 Tannic acid 9 Water 81.7 The in vitro release of the active ingredients from the powders obtained from these formulations was tested. The results are summarized in Tables 3-4.
Table 3: In ease of NicotineFormulation Vitro Rel from 245-49 Time (hr) % Cum Rel % Cum Rel 0.25 I .99 3.50 0.5 3.19 5.45 1 5.18 7.39 2 8.76 10.50 3 12.35 16.34 4 17.93 23.35 5 21.91 26.85 6 25.10 30.74 7 27.09 35.80 Table 4: In Vitro Release of Pilocarpine from Formulation Time (hr) % Cum Rel 0.25 2.77 0.5 5.03 1 7.28 2 14.22 3 19.77 4 25.32 5 31.56 6 37.46 7 42.66 8 47.86 WO 99/04764 ~ PCT/US98115096 The results show that one can control the release of highly soluble drugs with these formulations. The release can take place over many hours with less than half the drug having been released in eight hours.
Example 2 Control Over the Rate of Drug Release in Prolonged Controlled Release of a Highly Soluble Drug: I
Materials and Methods Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Sodium salicylate was purchased from Merck.
Preparation of Formulation The powder of gelatin-tannic acid was formulated with the highly soluble drug sodium salicylate and prepared using two different ratios of ethanol and water. in formulation 245-66A the weight proportion of the solvent was 3:1 {ethanol : water) and in formulation 245-68A it was 1:1.
Results The formulations used are described in Tables 5-6.
Table 5: Liquid Formulation 245-66A
Ingredient Weight Hydrolyzed gelatin 10 Sodium Salicylate I
Water 19 Ethanol 60 Tannic acid l0 Table 6: Liquid Formulation Ingredient Weight Hydrolyzed gelatin 10 Sodium Salicylate 1 Water 39.5 Tannic acid 10 Ethanol 39.5 1 S In vitro release studies were carried out on the powders obtained from these formulations as in Example 1.
The results of the in vitro release studies are summarized in Tables 7 and 8.
WO 99!04764 PCT/US98/15096 Table 7: In Vitro Release of Sodium Salicyiate from Formulation Time (hr) % Cumulative % Cumulative Release ._ Release 0.25 I 5 24 0.5 21 34 Table 8: In Vitro Release of Sodium Salicylate from Formulation Time (hr) % Cumulative % Cumulative Release Reiease 0.25 9 14 0.5 15 20 One can see that a high proportion of water in the solvent mixture decreases the release rate of the active ingredient while a higher ethanol content increases the release rate. In both cases one has prolonged release of the highly soluble substance, sodium salicylate, from the matrix.
Example 3 Control Over the Rate of Drug Release in Prolonged Controlled Release of a Highly Soluble Drug: ll Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulation The powder of gelatin-tannic acid was formulated with the highly soluble drug nicotine and prepared using two different ratios of ethanol and water. In formulation 245-70 the weight proportion of the solvent was 3:1 (ethanol:water) and in formulation 245-49 it was 1:1.
Results The formulations are given in Tables 9 and 10.
WO 99/04764 ~ PCT/US98/15096 Table 9: Liquid Formulation Ingredient Weight Hydrolyzed gelatin10 1N HCl 5 Nicotine 1 Water 17 Ethanol 57 Tannic acid 10 Table 10: Liquid Formulation Ingredient Weight Hydrolyzed gelatin10 Nicotine 1 Water 34 Ethanol 39 Tannic acid 10 In vitro release studies were carried out on the powders obtained from these formulations as in Example 1.
The release pattern of nicotine from formulations 245-70 and 241-49 is illustrated in Tables 11 and 12.
Table 11: Release of Nicotine mulation 245-70 from for Time (hr) % Cumulative % Cumulative Release Release 0.25 15 12 0.5 20 17 Table 12: ReleaseNicotine from ation 245-49 of formul Time (hr) % Cumulative % Cumulative Release Release 0.25 4.5 4 0.5 6 S
As it was shown for sodium salicylate, the effect of the solvent mixture was achieved with nicotine also. Increased amounts of water in the solvent mixture during the preparation of the formulation results in slower release.
WO 99/04764 ~ PCTIi1S98/15096 Example 4 Prolonged Sustained Release of Nicotine from a Pharmaceutical Oral Patch Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit L-100, Eudragit 30D-SS and triethyl citrate NF were purchased from Rhom Pharma.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulations The patch was formed by mixing the powder formed from Formulation 245-70 (Table 9) with an ethanolic solution of Eudragit L-100 and a plasticizer.
The mixture was transferred to plastic molds and dried to form an adhesive pharmaceutical oral patch.
In Vitro Release The dry patches (300 mg) were stirred in 100 ml buffer (phosphate, 0.01 M, pH 7.4) at room temperature. Samples of the solution (0.5 ml) were analyzed.
Results In vitro release experiments were carried out. The results are summarized in Table 13.
Table 13: In Vitro Release of Nicotine from a Pharmaceutical Oral Patch Time (hr) % Cumulative % Cumulative Release _ Release 0.25 2 3.5 0.5 3.2 5.5 1 5.2 7.4 2 8.8 10.5 3 12.4 16.3 4 17.9 23.4 5 21.9 26.9 6 25.1 30.7 7 27.1 35.8 Example S
Prolonged Sustained Release of Pilocarpine from a Pharmaceutical Oral Patcl:
Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit L-100, Eudragit 30D-SS and triethyl citrate NF were purchased from Rhom Pharma.
Pilocarpine was purchased from Laob.
Preparation of Formulations The patch was formed by mixing the powder formed from Formulation 245-43C (Table 2) with a water suspension of Eudragit L 30D-55.
The mixture was transferred to plastic molds and dried to form a S pharmaceutical oral patch.
In Vitro Release The dry patches (300 mg) were stirred in 100 ml buffer (phosphate, 0.01 M, pH 7.4) at room temperature. Samples (0.5 ml) of the solution were analyzed.
Results In vitro release experiments were carried out. The results are summarized in Table 14.
Table 14: In Vitro Release of Pilocarpine from a Pharmaceutical Oral Patch ~ Time (hr) % Cumulative % Cumulative Release Release 0.25 7.9 4.3 0.5 11.6 6.2 1 16.1 8.5 3 27 15.1 4 31.1 17.8 5 32.6 21.6 The results show that one can control the release of soluble drugs from a pharmaceutical oral patch for several hours.
Example 6 In Vitro Release of Nicotine from an _ Adhesive Pharmaceutical Oral Patch Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit L-100 and Triethyl Citrate NF were purchased from Rhom Pharma.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulations The patch was formed by mixing the powder formed from liquid Formulation 158-72 (Table 15), with an ethanolic solution of Eudragit L-100 and a plasticizer.
The mixture was transferred to plastic molds and dried to form an adhesive pharmaceutical oral patch.
Table 15: Liquid Formulation 158-72 Ingredient Weight Hydrolyzed gelatin28 37% HCI 0.5 Nicotine t Water 47.5 Ethanol 3 Tannic acid 20 In Vivo Release Experiment The pharmaceutical oral patch (190 mg), containing 2 mg nicotine, was attached to the buccal side of an upper molar tooth by means of self adhesion.
Saliva samples were expectorated at given time intervals and tested for nicotine content.
Results One volunteer wore the pharmaceutical oral patch for a period of four hours. The patch conformed to the contour of the tooth and was comfortable to wear. Saliva samples were collected and analyzed by chromatography. The results are listed in Table 16.
Table 16: In Vivo Release of Nicotine from a Pharmaceutical Oral Patch Time (min) Concentration (ppm) 0 0.3 15 13.4 30 25.1 60 23.8 90 51.6 120 20.1 180 26.3 240 18.1 The results indicate that clinically significant concentrations of nicotine as an example of soluble drug, can be maintained in the oral cavity for several hours.
The pharmaceutical oral patch self adhered to the tooth for the entire period of the experiment.
WO 99/04764 - PCT/C1S98l15096 Example 7 In Vivo Release of Nicotine from a Second Adhesive Pharmaceutical Oral Patch Materials Hydrolyzed gelatin was purchased from Croda.
Tannic acid USP was purchased from Merck.
Eudragit 30D-55 and Triethyl Citrate NF were purchased from Rhom Pharma.
Nicotine was purchased from The Nicobrand Company.
Preparation of Formulations The patch was formed by mixing the powder formed from liquid Formulation 41 B001 SL (Table 17) with an aqueous suspension of Eudragit L
30D-55 and a plasticizer.
The mixture was transferred to plastic molds and dried to form an adhesive pharmaceutical oral patch.
Table 17: Liquid Formulation 41BOO1SL
Ingredient Weight Hydrolyzed gelatin27.5 37% HCl I
Nicotine I .6 Water 46.5 Ethanol 3.2 Tannic acid 20.1 *rB
WO 99/04764 ~ PCT/US98/15096 In Vivo Release Experiment The pharmaceutical oral patch (115 mg), containing 2 mg nicotine, was attached to the buccal side of an upper molar tooth by means of self adhesion.
Saliva samples were expectorated at given time intervals and tested for nicotine content.
Results One volunteer wore the pharmaceutical oral patch for a period of four hours. The patch conformed to the contour of the tooth and was comfortable to wear. Saliva samples were collected and analyzed by chromatography. The results are listed in Table 18.
Table 18: In Vivo Release of Nicotine from a Pharmaceutical Oral Patch Time (min) Concentration (ppm) 0 0.3 30 2.7 60 5.6 120 11.3 180 28.6 240 0.7 The results indicate that clinically significant concentrations of nicotine can be maintained in the oral cavity for several hours. The pharmaceutical oral patch self adhered to the tooth for the entire period of the experiment.
Example 8 Release of Liposome Encapsulated Nicotine from Pharmaceutical Oral Patches Nicotine was entrapped in liposomes of both the multilamellar vesicle (MLV) and small unilamellar vesicle (SUV) type. The formulations used for the formation of the Iiposomes are given in Table 19.
Table 19: Ingredients of MLV and SUV Liposomes:
Type Materials weight(g)mole%
NlCOtine Egg Phosphatidylcholine1 60.9 (PC) 99% Synthetic Liposomes 0.1 6.6 MLV
Phosphatidylethanolamine (PE) 99% 0 32 Cholestero195% . .
NiCOtine Soybean Phosphatidyicholine1,2 62.8 (PC) Liposomes Synthetic 0.12 6.8 SUV
Phosphatidylethanolamine (PE) 99% 0 4 Cholestero195% . .
The phospholipids and lipids were dissolved in 25 ml chloroform:methanol (2:1 ) in a round bottom flask of 100-1000 ml. The lipid solution was dried for 2 hours to form a lipid film onto the sides of the flask, using a rotary evaporator apparatus. The lipids were hydrated by addition of 10-20 ml H20 or PBS
(phosphate buffered saline) solution (0.01 M, pH 7.4), followed by vortexing and shaking in a 37°C water bath, for 2-4 hours to form MLV liposomes. The liposomes were characterized by standard chemical and electron microscope techniques.
MLV Nicotine Liposomes:
Nicotine (0.2 ml), a volatile and water soluble drug, was dissolved in an aqueous medium and added to the lipid film at the hydration step.
SUV Nicotine Liposomes:
WO 99/04764 ~ PCT/US98/15096 Nicotine (0.2 ml), in an aqueous medium was added to placebo liposomes (MLV) followed by 1 hour sonication to form nicotine liposomes of type SUV.
The percent entrapment of the nicotine was determined for each type of liposome and is shown in Table 20.
Table 20: Efficiency of Nicotine Encapsulation in Liposomes:
Type of liposomes % of encapsulation One can see that nicotine encapsulation in the liposomes was as expected for a water soluble drug. More drug was encapsulated in the SUV than in the MLV due to the higher percent internal aqueous volume in this form of liposome.
The liposomes were stored at 4°C (closed tightly).
Pharmaceutical oral patches were made using nicotine trapped in MLV
liposomes with and without an outer polymer matrix. The other ingredients of the patches are given in Table 21.
Table 21: Non Active Ingredients of Patches:
Materials Batch# Batch# Batch# Batch# Batch#
~'gt w'gt ~'gt ~'gt H'gt (g) fig) fig) (g) (g) H20 3.3 3.3 3.1 33 33 BycoE 2.6 2.6 3.1 26 26 H20 1.1 1.1 1.3 11 11 Ethanol 0.3 0.3 - 3 3 Tannic Acid 1.9 1.9 1.7 19 19 MatrIX(Elldr.L-30D+Glycerin)'~' - -lVlatCIX (Eudr.L-100+Ethanol)- 'f' - + +
Patches of Batches# 285-23A, 285-23B:
2g of MLV liposomes containing entrapped nicotine were suspended in water. BycoE~'~"'' was added and finally a solution of tannic acid in ethanol-water was added. The precipitate was dried at 50 ° C, ground to a powder and mixed with a polymer matrix based on EudragitT"" (approx. 1:1 ). Polypropylene molds were filled with the mixture (190mg/well) and dried at 35°C. These patches contain ~2 mg nicotine each and are formed with an outer polymer matrix.
Patches of Batch# 285-28:
Solution of tannic acid in water was added dropwise into solution of Byco 1 O ET"'. 0.45g of the tannic acid-Byco preparation were mixed with 0.63g of MLV
liposomes containing entrapped nicotine. Polypropylene molds were filled with the mixture (280mg/well) and dried at 35 °C in the oven. These patches contain ~2 mg nicotine each and are formed without an outer polymer matrix.
Patches without liposomes # 49A004 and 158-64:
Nicotine neutralized with HCl was dissolved in water. Byco ETM was added and finally a solution of tannic acid in ethanol-water was added. The precipitate was dried at 50°C, ground to a powder and mixed with a polymer matrix based on EudragitT"" (approx. 1:1 ). Polypropylene molds were filled with the mixture (190mg/well) and dried at 35 °C. These patches contain ~2 mg nicotine each and are formed with an outer polymer matrix.
Release Assays:
In vitro: Patches containing liposomes were introduced into dialysis tubes with a molecular weight cutoff of 50,000 and stirred in bulk solutions of 50-ml phosphate buffered saline (PBS) (O.O1M, pH 7.4). 0.2m1 samples were collected at times 0-7h. The nicotine was determined by a validated HPLC
method.
In vivo: The pharmaceutical oral patch was attached to an upper back tooth. Saliva samples were collected at times 0-180 min. The nicotine was determined by a validated HPLC method.
Results in Vitro:
The average results of release of nicotine from the in vitro pharmaceutical oral patches are summarized in Figure 1.
The release of drug from liposomal patches #285-28 (V) was slower than from the non liposomal nicotine patches #49A004 (VI-VIII). The release of nicotine from both of these types of patches was characterized by a single rate constant. In contrast, the release profile of nicotine from liposomal patches #285-23A (I and II) and #285-23B (III and IV), was characterized by a two phase release of the drug and was also slower than the non-liposomal formulation.
Results in Vivo:
The release experiment of nicotine in vivo was performed, using patch #285-28 containing centrifuged nicotine liposomes type MLV and compared to non-liposomal nicotine patch #158-64. The results are shown in Figure 2.
One sees that salivary concentrations of nicotine were higher for the formulation without liposomes. The profiles of release were similar.
Example 9 Release of Liposome Encapsulated Flurbiprofen from Pharmaceutical Oral Patches Flurbiprofen was entrapped in multilamellar vesicle type liposomes as follows:
Soybean phosphatidylcholine ( 14 gm) was dissolved in 100 ml ethanol in a 1000 ml round bottom flask along with 2.3 gm flurbiprofen. The lipid solution was dried for 1.5 hours to form a lipid film with flurbiprofen dispersed therein.
onto the sides of the flask, using a rotary evaporator apparatus. The lipids were hydrated by addition of 140 ml HzO, followed by rotation for 2 hours-and slow stirring for 1 hour to form MLV liposomes. The liposomes were characterized by standard chemical and electron microscope techniques. The non-encapsulated flurbiprofen was removed by dialysis. The liposomes were obtained by centrifugation at 10°C for 1 hour at 17500 rpm.
Patches of Batch# 285- 62:
Tannic acid (1.7 gm) in 1.3 gm water was added dropwise to a solution of 3.1 gm hydrolyzed gelatin (BycoETM) in water. The tannic acid - hydrolyzed gelatin preparation was mixed with 9.6 gm of MLV liposomes containing entrapped flurbiprofen. Polypropylene molds were filled with the mixture (200 mg/well) and the patches were dried in an oven at 30°C.
Release Assays:
In vitro: Patches containing liposomes were stirred in bulk solutions of 100 ml PBS (0.01 M, pH 7.4). 0.2m1 samples were collected at times 0-7h. The flurbiprofen was determined by a validated HPLC method.
Results in Vitro:
The average results of the in vitro release of flurbiprofen from the pharmaceutical oral patches are summarized in Figure 3 and Table 22. One can see clear sustained release of the flurbiprofen from the patches.
Table 22: Cumulative Release of Flurbiprofen Time % cumulative release 15 7.53 30 10.94 60 ~ 15.37 -SS-120 21.12 180 27.19 240 30.81 300 33.66 360 37.44
Claims (41)
1. A liquid composition comprising hydrolyzed gelatin and tannic acid or tannin.
2. A liquid composition comprising hydroxypropylmethylcellulose and tannic acid or tannin.
3 . A liquid composition consisting essentially of hydroxyethylcellulose and tannic acid or tannin.
4. A liquid composition comprising a protein and tannic acid or tannin, wherein said liquid composition dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom or forms a precipitate of said protein and tannic acid or tannin that dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom.
5. The liquid composition of claim 4 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, collagen and albumin.
6. A liquid composition comprising a cellulosic polymer selected from the group consisting of hydroxyethylcellulose and hydroxypropylmethylcellulose, and tannic acid or tannin, wherein said liquid composition dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom.
7. A liquid composition comprising a protein and tannic acid or tannin, wherein said liquid composition dries to form an adhesive solid composition capable of controlled release of a pharmaceutical compound therefrom or forms a precipitate of said protein and tannic acid or tannin that dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom.
8. The liquid composition of claim 7 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, collagen and albumin.
9. A liquid composition comprising a cellulosic polymer selected from the group consisting of hydroxyethylcellulose and hydroxypropylmethylcellulose, and tannic acid or tannin, wherein said liquid composition dries to form an adhesive solid composition capable of controlled release of a pharmaceutical compound therefrom.
10. A liquid composition comprising a protein selected from the group consisting of hydrolyzed gelatin, albumin, and collagen, and tannic acid or tannin and a pharmaceutical compound.
11. A liquid composition comprising hydroxypropylmethylcellulose and tannic acid or tannin and a pharmaceutical compound.
12. A liquid composition comprising a mixture of a protein and tannic acid or tannin and a pharmaceutical compound.
13. The liquid composition of claim 12 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, albumin, and collagen.
14. A liquid composition comprising a mixture of hydroxyethylcellulose and tannic acid or tannin and a pharmaceutical compound.
-58-~
-58-~
15. A liquid composition comprising a protein and tannic acid or tannin, and a pharmaceutical, wherein said liquid composition dries to form a solid composition capable of controlled release of said pharmaceutical therefrom or forms a precipitate of said protein and tannic acid or tannin that dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom.
16. The liquid composition of claim 15 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, collagen and albumin.
17. A liquid composition comprising a cellulosic polymer selected from the group consisting of hydroxyethylcellulose and hydroxypropylmethylcellulose, and tannic acid or tannin, and a pharmaceutical, wherein said liquid composition dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom.
18. A liquid composition comprising a protein and tannic acid or tannin, and a pharmaceutical, wherein said liquid composition dries to form an adhesive solid composition capable of controlled release of said pharmaceutical therefrom or forms a precipitate of said protein and tannic acid or tannin that dries to form a solid composition capable of controlled release of a pharmaceutical compound therefrom.
19. The liquid composition of claim 18 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, collagen and albumin, and tannic acid or tannin.
20. A liquid composition comprising a cellulosic polymer selected from the group consisting of hydroxyethylcellulose and hydroxypropylmethylcellulose, and tannic acid or tannin, and a pharmaceutical, wherein said liquid composition dries to form an adhesive solid composition capable of controlled release of a pharmaceutical therefrom.
21. A liquid composition of claims 15, 17, 18 or 20 wherein the pharmaceutical agent is entrapped in liposomes or microcapsules, microspheres, nanocapsules or nanospheres.
22. A liquid composition according to claim 21 where said liposome comprises phospholipids and/or sphingolipids such as soybean lecithin, egg lecithin, soybean phosphatidylcholine, egg phosphatidylcholine, synthetic phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidylethanolamine, and sphingomyelin alone or in mixtures.
23. A liquid composition according to claim 21 where said microcapsule, microsphere, nanocapsule or nanosphere comprises polymers such as polyalkyl methacrylate such as polymethylmethacrylate, polyalkylcyanoacrylates such as polymethylcyanomethacrylate, polyesters such as polylactic acid and polylactic/glycolic acid copolymers, cellulose derivatives such as ethylcellulose and cellulose acetate and proteins such as albumin, gelatin, and hydrolyzed gelatin, and polysaccharides such as sodium alginate, pectin, chitosan, guar gum, and xanthan gum.
24. A solid composition comprising a cellulosic polymer selected from the group consisting of hydroxyethylcellulose and hydroxypropylmethylcellulose and tannic acid or tannin, and a pharmaceutical, wherein said solid composition is capable of controlled release of said pharmaceutical therefrom.
25. A solid composition comprising a mixture of a protein, and tannic acid or tannin, and a pharmaceutical, wherein said solid composition is capable of controlled release of said pharmaceutical therefrom.
26. The solid composition of claim 22 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, albumin, and collagen.
27. A solid adhesive composition comprising a protein, and tannic acid or tannin, and a pharmaceutical, wherein said solid adhesive composition is capable of controlled release of said pharmaceutical therefrom.
28. The solid adhesive composition of claim 24 wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, albumin, and collagen.
29. A solid adhesive composition comprising a pharmaceutical and a cellulosic polymer selected from the group consisting of hydroxyethylcellulose and hydroxypropylmethylcellulose and tannic acid or tannin, wherein said solid adhesive composition is capable of controlled release of said pharmaceutical therefrom.
30. A method for producing a solid composition capable of the controlled release of a pharmaceutical, said method comprising:
(1) providing a protein, tannic acid or tannin, and a pharmaceutical, in a liquid solution of a solvent selected from the group consisting of water, alcohol and water:alcohol, (2) allowing a precipitate to form between the protein and tannic acid or tannin, thus entrapping the pharmaceutical in the precipitate, (3) allowing said precipitate to dry, thereby forming said solid composition.
-61-~
(1) providing a protein, tannic acid or tannin, and a pharmaceutical, in a liquid solution of a solvent selected from the group consisting of water, alcohol and water:alcohol, (2) allowing a precipitate to form between the protein and tannic acid or tannin, thus entrapping the pharmaceutical in the precipitate, (3) allowing said precipitate to dry, thereby forming said solid composition.
-61-~
31. The method of claim 27, wherein release of said pharmaceutical from said solid composition is controlled by the alcohol:water ratio of said solution.
32. The method of claim 27, wherein release of said pharmaceutical is controlled by the further steps of:
(1) adding a second polymer selected from the group consisting of Eudragit TM polymers, hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, pectin, calcium pectinate, alginic acid, calcium alginate, cellulose acetate phthalate, carbopol, guar gum, gum tragacanth, gum acacia, and chitosan, in solution or suspension and a plasticizer to said dried precipitate, (2) allowing the components in step (1) to dry.
(1) adding a second polymer selected from the group consisting of Eudragit TM polymers, hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, pectin, calcium pectinate, alginic acid, calcium alginate, cellulose acetate phthalate, carbopol, guar gum, gum tragacanth, gum acacia, and chitosan, in solution or suspension and a plasticizer to said dried precipitate, (2) allowing the components in step (1) to dry.
33. The method of claim 29, wherein said Eudragit TM polymer is selected from the group consisting of Eudragit TM L-100, Eudragit TM L 30D-55, Eudragit TM S-100, Eudragit TM NE-100, Eudragit TM NE-30, Eudragit TM RL, and Eudragit TM RS.
34. The method of claim 29, wherein controlled release is further adjusted by the alcohol:water ratio in said solution.
35. The method of either of claims 28 or 31, wherein said alcohol is ethanol.
36. The method of claim 29 wherein the release of said pharmaceutical is further controlled by the addition of pH adjusting agents, release adjusting agents, or solubility adjusting agents, to the solution or suspension of the second polymer.
37. The method of claim 29 wherein said pharmaceutical or a different pharmaceutical is included in the solution or suspension of said second polymer.
3 8. The method of any of claims 27-3 2, wherein said protein is selected from the group consisting of gelatin, hydrolyzed gelatin, albumin, and collagen.
39. A method of using the compositions of any of claims 22-26, wherein said composition is used to release a pharmaceutical into the oral cavity.
40. The method of claim 36, wherein the form of said composition is as a tooth patch as described herein.
41. The method of claim 37, wherein said pharmaceutical is selected from the group consisting of nicotine, nicotine salts, nicotine polymer complexes, lidocaine, piroxicam, flurbiprofen, dihydroergotamine mesylate, ergotamine tartarate, sumatriptan succinate, isosorbide dinitrate, isosorbide mononitrate, nifedipine, ondansetron hydrochloride, and peptide drugs.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89912197A | 1997-07-23 | 1997-07-23 | |
US08/899,121 | 1997-07-23 | ||
PCT/US1998/015096 WO1999004764A1 (en) | 1997-07-23 | 1998-07-22 | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2296654A1 true CA2296654A1 (en) | 1999-02-04 |
Family
ID=25410514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296654A Abandoned CA2296654A1 (en) | 1997-07-23 | 1998-07-22 | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1003483A1 (en) |
JP (1) | JP2001510788A (en) |
KR (1) | KR20010021911A (en) |
AU (1) | AU8578498A (en) |
BR (1) | BR9811478A (en) |
CA (1) | CA2296654A1 (en) |
HU (1) | HUP0002490A2 (en) |
IL (1) | IL134151A0 (en) |
NO (1) | NO20000284L (en) |
WO (1) | WO1999004764A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021033180A1 (en) * | 2019-08-16 | 2021-02-25 | Adel Penhasi | Adhesive drug delivery microparticles and a product comprising thereof |
CN115477920A (en) * | 2021-06-15 | 2022-12-16 | 西南大学 | Preparation method of tannin-based underwater adhesive and product |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
JP2004501190A (en) * | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | Rapidly expanding compositions for gastric retention and controlled release of therapeutic agents and dosage forms containing the compositions |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
ES2288823T3 (en) * | 2000-09-01 | 2008-02-01 | Cognis Ip Management Gmbh | AGENT FOR ORAL AND DENTAL CARE. |
JP4820024B2 (en) * | 2001-01-10 | 2011-11-24 | 昭和薬品化工株式会社 | Local anesthetic composition |
JP5089840B2 (en) * | 2001-09-25 | 2012-12-05 | 救急薬品工業株式会社 | Nicotine-containing film preparation |
EP2338475A3 (en) * | 2001-11-05 | 2012-08-08 | Orahealth Corporation | Treating canker sores with patches to speed healing and relieve pain |
ES2536713T3 (en) * | 2003-03-12 | 2015-05-27 | Epitome Pharmaceuticals Limited | Compositions for lipophilic skin of rapid absorption and uses thereof |
US20040185009A1 (en) * | 2003-03-19 | 2004-09-23 | Dexcel Pharma Technologies Ltd. | Composition and device for treating periodontal diseases |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
WO2005046363A2 (en) | 2003-11-07 | 2005-05-26 | U.S. Smokeless Tobacco Company | Tobacco compositions |
US20050207993A1 (en) * | 2003-11-13 | 2005-09-22 | Russel Bazemore | Method and composition for breath freshening |
DK1750683T3 (en) | 2004-04-23 | 2013-04-15 | Amgen Inc | Prolonged-release formulations |
WO2007118653A2 (en) * | 2006-04-11 | 2007-10-25 | Koko Kosmetikvertrieb Gmbh & Co. Kg | Nanoparticle containing nicotine and/or cotinine, dispersions and use thereof |
US8642088B2 (en) | 2009-09-04 | 2014-02-04 | Wisconsin Alumni Research Foundation | Tannin-chitosan composites |
KR101307367B1 (en) * | 2010-09-14 | 2013-09-25 | 주식회사 이노테라피 | Adhesive composition comprising tannin, polyethylene glycol, and water, low carbon alcohol or the mixture thereof |
US8865198B2 (en) | 2010-10-25 | 2014-10-21 | Dexcel Pharma Technologies Ltd. | Method for treating a periodontal disease |
FR2972327B1 (en) * | 2011-03-11 | 2017-08-11 | Laboratoires Le Stum | MUCOADHESIVE NUTRACEUTICAL COMPOSITION COMPRISING ANTIOXIDANT ASSOCIATION |
GB2496654A (en) * | 2011-11-18 | 2013-05-22 | Reckitt & Colman Overseas | Self-assembling peptides |
US20130158132A1 (en) * | 2011-12-19 | 2013-06-20 | Aida Salatinjants | Formulation Solution Adapted To Prolong Plasma Times Of Drugs In Mammals Including Humans |
WO2015167257A1 (en) * | 2014-04-29 | 2015-11-05 | 포항공과대학교 산학협력단 | Composition for oral application and method for preparing same |
RU2606589C2 (en) * | 2015-02-16 | 2017-01-10 | Александр Александрович Кролевец | Method of producing tannin nanocapsules |
US10532046B2 (en) * | 2015-12-03 | 2020-01-14 | Niconovum Usa, Inc. | Multi-phase delivery compositions and products incorporating such compositions |
KR20230146888A (en) | 2022-04-13 | 2023-10-20 | 경북대학교 산학협력단 | Drug sustained-release self-healing coating layer for dental restoration and manufacturing method thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB104609A (en) * | 1916-06-05 | 1917-03-15 | Monneron & Guye | A Method of Manufacturing a Medicinal Aluminium Preparation. |
GB918754A (en) * | 1959-08-14 | 1963-02-20 | Armour & Co | Improvements in or relating to corticotrophin preparations |
GB2036750B (en) * | 1978-11-23 | 1983-05-05 | Payne M | Tannin complexes |
JPS5846011A (en) * | 1981-09-14 | 1983-03-17 | Kao Corp | Hair treatment |
JPH01166763A (en) * | 1987-12-22 | 1989-06-30 | Nitta Gelatin Inc | Medical and dental curable material |
AU2252388A (en) * | 1988-05-02 | 1989-11-29 | Zila Pharmaceuticals | Compositions and in situ methods for forming films on body tissue |
JPH04114655A (en) * | 1990-09-03 | 1992-04-15 | Shinonaga Kasei Kk | Hard composition for medical use |
JPH04312522A (en) * | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | Production of sustained release tablet |
JP3496727B2 (en) * | 1993-12-27 | 2004-02-16 | 救急薬品工業株式会社 | Pharmaceutical base |
JPH08319232A (en) * | 1995-03-22 | 1996-12-03 | Takeda Chem Ind Ltd | Particulate composition |
JP2885668B2 (en) * | 1995-09-29 | 1999-04-26 | 沢井製薬株式会社 | Teprenone formulation |
-
1998
- 1998-07-22 CA CA002296654A patent/CA2296654A1/en not_active Abandoned
- 1998-07-22 WO PCT/US1998/015096 patent/WO1999004764A1/en not_active Application Discontinuation
- 1998-07-22 AU AU85784/98A patent/AU8578498A/en not_active Abandoned
- 1998-07-22 HU HU0002490A patent/HUP0002490A2/en unknown
- 1998-07-22 BR BR9811478-6A patent/BR9811478A/en not_active Application Discontinuation
- 1998-07-22 JP JP2000503824A patent/JP2001510788A/en not_active Withdrawn
- 1998-07-22 KR KR1020007000475A patent/KR20010021911A/en not_active Application Discontinuation
- 1998-07-22 IL IL13415198A patent/IL134151A0/en unknown
- 1998-07-22 EP EP98936955A patent/EP1003483A1/en not_active Withdrawn
-
2000
- 2000-01-20 NO NO20000284A patent/NO20000284L/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021033180A1 (en) * | 2019-08-16 | 2021-02-25 | Adel Penhasi | Adhesive drug delivery microparticles and a product comprising thereof |
CN115477920A (en) * | 2021-06-15 | 2022-12-16 | 西南大学 | Preparation method of tannin-based underwater adhesive and product |
Also Published As
Publication number | Publication date |
---|---|
KR20010021911A (en) | 2001-03-15 |
BR9811478A (en) | 2000-08-15 |
NO20000284D0 (en) | 2000-01-20 |
NO20000284L (en) | 2000-03-22 |
WO1999004764A1 (en) | 1999-02-04 |
IL134151A0 (en) | 2001-04-30 |
JP2001510788A (en) | 2001-08-07 |
EP1003483A1 (en) | 2000-05-31 |
HUP0002490A2 (en) | 2000-12-28 |
AU8578498A (en) | 1999-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6197331B1 (en) | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity | |
CA2296654A1 (en) | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity | |
EP0973497B1 (en) | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces | |
AU746339B2 (en) | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces | |
KR101595139B1 (en) | Gingival wafer | |
US20050048102A1 (en) | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces | |
JPH0584282B2 (en) | ||
WO2020051048A1 (en) | Cannabinoid and menthol compositions and methods | |
WO2020051047A2 (en) | Cannabinoid and anesthetic compositions and methods | |
WO2015101907A1 (en) | Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels | |
Pathan et al. | Buccoadhesive drug delivery systems-extensive review on recent patents | |
Pattnaik et al. | Periodontal muco-adhesive formulations for the treatment of infectious periodontal diseases | |
WO2021177937A1 (en) | Cannabinoid and menthol compositions and methods | |
CZ2000181A3 (en) | Tannic acid-polymer composition for controlled release of pharmaceutical agents, particularly in mouth cavity | |
AU769500B2 (en) | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces | |
Repka et al. | Matrix-and reservoir-based transmucosal delivery systems: tailoring delivery solutions | |
WO2021177938A1 (en) | Veterinary cannabinoid and menthol compositions and methods | |
WO2021177936A1 (en) | Cannabinoid and anesthetic compositions and methods | |
WO2021177939A1 (en) | Veterinary cannabinoid, menthol and anesthetic compositions and methods | |
kumar Yamsani | International Journal of Pharmacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |